TW201006928A - A universal baculovirus surface display system and application inproduction of subunit vaccine - Google Patents
A universal baculovirus surface display system and application inproduction of subunit vaccine Download PDFInfo
- Publication number
- TW201006928A TW201006928A TW97130055A TW97130055A TW201006928A TW 201006928 A TW201006928 A TW 201006928A TW 97130055 A TW97130055 A TW 97130055A TW 97130055 A TW97130055 A TW 97130055A TW 201006928 A TW201006928 A TW 201006928A
- Authority
- TW
- Taiwan
- Prior art keywords
- virus
- ser
- thr
- protein
- recombinant
- Prior art date
Links
- 241000701447 unidentified baculovirus Species 0.000 title claims abstract description 96
- 229940031626 subunit vaccine Drugs 0.000 title abstract description 8
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 102
- 241000700605 Viruses Species 0.000 claims abstract description 68
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 52
- 239000013598 vector Substances 0.000 claims abstract description 33
- 230000001086 cytosolic effect Effects 0.000 claims abstract description 16
- 210000004027 cell Anatomy 0.000 claims description 73
- 244000144977 poultry Species 0.000 claims description 34
- 241000238631 Hexapoda Species 0.000 claims description 31
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 21
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 21
- 241000710777 Classical swine fever virus Species 0.000 claims description 13
- 108091008146 restriction endonucleases Proteins 0.000 claims description 12
- 238000003776 cleavage reaction Methods 0.000 claims description 11
- 230000007017 scission Effects 0.000 claims description 11
- 229960005486 vaccine Drugs 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 239000013604 expression vector Substances 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 8
- 238000010171 animal model Methods 0.000 claims description 8
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 8
- 108010067390 Viral Proteins Proteins 0.000 claims description 6
- 101150082674 E2 gene Proteins 0.000 claims description 5
- 102000029797 Prion Human genes 0.000 claims description 5
- 108091000054 Prion Proteins 0.000 claims description 5
- 241000282898 Sus scrofa Species 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 230000006798 recombination Effects 0.000 claims description 3
- 238000005215 recombination Methods 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 238000003259 recombinant expression Methods 0.000 claims 3
- 101150028074 2 gene Proteins 0.000 claims 1
- 241000271566 Aves Species 0.000 claims 1
- 101900173079 Classical swine fever virus Envelope glycoprotein E2 Proteins 0.000 claims 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 238000001814 protein method Methods 0.000 claims 1
- 101710141347 Major envelope glycoprotein Proteins 0.000 abstract description 32
- 230000014509 gene expression Effects 0.000 abstract description 9
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract description 7
- 241001122767 Theaceae Species 0.000 description 25
- 241000282326 Felis catus Species 0.000 description 18
- 238000012360 testing method Methods 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 239000012634 fragment Substances 0.000 description 12
- 239000013605 shuttle vector Substances 0.000 description 11
- 238000003752 polymerase chain reaction Methods 0.000 description 10
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 9
- 238000010276 construction Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 210000004779 membrane envelope Anatomy 0.000 description 9
- 108010057821 leucylproline Proteins 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 241000712461 unidentified influenza virus Species 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 235000013601 eggs Nutrition 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 101710182846 Polyhedrin Proteins 0.000 description 6
- KKKVOZNCLALMPV-XKBZYTNZSA-N Ser-Thr-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O KKKVOZNCLALMPV-XKBZYTNZSA-N 0.000 description 6
- LECUEEHKUFYOOV-ZJDVBMNYSA-N Thr-Thr-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](N)[C@@H](C)O LECUEEHKUFYOOV-ZJDVBMNYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 108010037850 glycylvaline Proteins 0.000 description 6
- 239000003547 immunosorbent Substances 0.000 description 6
- 108010053725 prolylvaline Proteins 0.000 description 6
- 238000009877 rendering Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 108010061238 threonyl-glycine Proteins 0.000 description 6
- 108010073969 valyllysine Proteins 0.000 description 6
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 5
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 description 5
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 4
- NHWYNIZWLJYZAG-XVYDVKMFSA-N Ala-Ser-His Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N NHWYNIZWLJYZAG-XVYDVKMFSA-N 0.000 description 4
- IJYZHIOOBGIINM-WDSKDSINSA-N Arg-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N IJYZHIOOBGIINM-WDSKDSINSA-N 0.000 description 4
- KMFPQTITXUKJOV-DCAQKATOSA-N Arg-Ser-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O KMFPQTITXUKJOV-DCAQKATOSA-N 0.000 description 4
- WSGVTKZFVJSJOG-RCOVLWMOSA-N Asp-Gly-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O WSGVTKZFVJSJOG-RCOVLWMOSA-N 0.000 description 4
- LKVKODXGSAFOFY-VEVYYDQMSA-N Asp-Met-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LKVKODXGSAFOFY-VEVYYDQMSA-N 0.000 description 4
- 241000714235 Avian retrovirus Species 0.000 description 4
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 4
- 101710125507 Integrase/recombinase Proteins 0.000 description 4
- AEDWWMMHUGYIFD-HJGDQZAQSA-N Leu-Thr-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O AEDWWMMHUGYIFD-HJGDQZAQSA-N 0.000 description 4
- NLQUOHDCLSFABG-GUBZILKMSA-N Ser-Arg-Arg Chemical compound NC(N)=NCCC[C@H](NC(=O)[C@H](CO)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O NLQUOHDCLSFABG-GUBZILKMSA-N 0.000 description 4
- QVOGDCQNGLBNCR-FXQIFTODSA-N Ser-Arg-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O QVOGDCQNGLBNCR-FXQIFTODSA-N 0.000 description 4
- IUXGJEIKJBYKOO-SRVKXCTJSA-N Ser-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CO)N IUXGJEIKJBYKOO-SRVKXCTJSA-N 0.000 description 4
- WUXCHQZLUHBSDJ-LKXGYXEUSA-N Ser-Thr-Asp Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CC(O)=O)C(O)=O WUXCHQZLUHBSDJ-LKXGYXEUSA-N 0.000 description 4
- GBIUHAYJGWVNLN-UHFFFAOYSA-N Val-Ser-Pro Natural products CC(C)C(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O GBIUHAYJGWVNLN-UHFFFAOYSA-N 0.000 description 4
- IECQJCJNPJVUSB-IHRRRGAJSA-N Val-Tyr-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(O)=O IECQJCJNPJVUSB-IHRRRGAJSA-N 0.000 description 4
- 108010038633 aspartylglutamate Proteins 0.000 description 4
- LXWYCLOUQZZDBD-LIYNQYRNSA-N csfv Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 LXWYCLOUQZZDBD-LIYNQYRNSA-N 0.000 description 4
- 108010050848 glycylleucine Proteins 0.000 description 4
- 239000010931 gold Substances 0.000 description 4
- 229910052737 gold Inorganic materials 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 208000002979 Influenza in Birds Diseases 0.000 description 3
- 108090001090 Lectins Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- AOILQMZPNLUXCM-AVGNSLFASA-N Val-Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN AOILQMZPNLUXCM-AVGNSLFASA-N 0.000 description 3
- 230000010530 Virus Neutralization Effects 0.000 description 3
- 206010064097 avian influenza Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000007910 cell fusion Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001493 electron microscopy Methods 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000009191 jumping Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000017105 transposition Effects 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 101710186708 Agglutinin Proteins 0.000 description 2
- JBGSZRYCXBPWGX-BQBZGAKWSA-N Ala-Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CCCN=C(N)N JBGSZRYCXBPWGX-BQBZGAKWSA-N 0.000 description 2
- JAMAWBXXKFGFGX-KZVJFYERSA-N Ala-Arg-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JAMAWBXXKFGFGX-KZVJFYERSA-N 0.000 description 2
- KIUYPHAMDKDICO-WHFBIAKZSA-N Ala-Asp-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O KIUYPHAMDKDICO-WHFBIAKZSA-N 0.000 description 2
- YSMPVONNIWLJML-FXQIFTODSA-N Ala-Asp-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(O)=O YSMPVONNIWLJML-FXQIFTODSA-N 0.000 description 2
- FUSPCLTUKXQREV-ACZMJKKPSA-N Ala-Glu-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O FUSPCLTUKXQREV-ACZMJKKPSA-N 0.000 description 2
- IXTPACPAXIOCRG-ACZMJKKPSA-N Ala-Glu-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N IXTPACPAXIOCRG-ACZMJKKPSA-N 0.000 description 2
- PAIHPOGPJVUFJY-WDSKDSINSA-N Ala-Glu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O PAIHPOGPJVUFJY-WDSKDSINSA-N 0.000 description 2
- FBHOPGDGELNWRH-DRZSPHRISA-N Ala-Glu-Phe Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O FBHOPGDGELNWRH-DRZSPHRISA-N 0.000 description 2
- MQIGTEQXYCRLGK-BQBZGAKWSA-N Ala-Gly-Pro Chemical compound C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O MQIGTEQXYCRLGK-BQBZGAKWSA-N 0.000 description 2
- JDIQCVUDDFENPU-ZKWXMUAHSA-N Ala-His-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CNC=N1 JDIQCVUDDFENPU-ZKWXMUAHSA-N 0.000 description 2
- CCDFBRZVTDDJNM-GUBZILKMSA-N Ala-Leu-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O CCDFBRZVTDDJNM-GUBZILKMSA-N 0.000 description 2
- 108010011667 Ala-Phe-Ala Proteins 0.000 description 2
- AUFACLFHBAGZEN-ZLUOBGJFSA-N Ala-Ser-Cys Chemical compound N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O AUFACLFHBAGZEN-ZLUOBGJFSA-N 0.000 description 2
- YNOCMHZSWJMGBB-GCJQMDKQSA-N Ala-Thr-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O YNOCMHZSWJMGBB-GCJQMDKQSA-N 0.000 description 2
- WNHNMKOFKCHKKD-BFHQHQDPSA-N Ala-Thr-Gly Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O WNHNMKOFKCHKKD-BFHQHQDPSA-N 0.000 description 2
- AAWLEICNDUHIJM-MBLNEYKQSA-N Ala-Thr-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](C)N)O AAWLEICNDUHIJM-MBLNEYKQSA-N 0.000 description 2
- PGNNQOJOEGFAOR-KWQFWETISA-N Ala-Tyr-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=C(O)C=C1 PGNNQOJOEGFAOR-KWQFWETISA-N 0.000 description 2
- UXJCMQFPDWCHKX-DCAQKATOSA-N Arg-Arg-Glu Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(O)=O)C(O)=O UXJCMQFPDWCHKX-DCAQKATOSA-N 0.000 description 2
- NABSCJGZKWSNHX-RCWTZXSCSA-N Arg-Arg-Thr Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H]([C@H](O)C)C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N NABSCJGZKWSNHX-RCWTZXSCSA-N 0.000 description 2
- RWCLSUOSKWTXLA-FXQIFTODSA-N Arg-Asp-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O RWCLSUOSKWTXLA-FXQIFTODSA-N 0.000 description 2
- HKRXJBBCQBAGIM-FXQIFTODSA-N Arg-Asp-Ser Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)O)N)CN=C(N)N HKRXJBBCQBAGIM-FXQIFTODSA-N 0.000 description 2
- QKSAZKCRVQYYGS-UWVGGRQHSA-N Arg-Gly-His Chemical compound N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O QKSAZKCRVQYYGS-UWVGGRQHSA-N 0.000 description 2
- VRZDJJWOFXMFRO-ZFWWWQNUSA-N Arg-Gly-Trp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O VRZDJJWOFXMFRO-ZFWWWQNUSA-N 0.000 description 2
- CRCCTGPNZUCAHE-DCAQKATOSA-N Arg-His-Ser Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CC1=CN=CN1 CRCCTGPNZUCAHE-DCAQKATOSA-N 0.000 description 2
- AFNHFVVOJZBIJD-GUBZILKMSA-N Arg-Met-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(O)=O AFNHFVVOJZBIJD-GUBZILKMSA-N 0.000 description 2
- ZEBDYGZVMMKZNB-SRVKXCTJSA-N Arg-Met-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCN=C(N)N)N ZEBDYGZVMMKZNB-SRVKXCTJSA-N 0.000 description 2
- FRBAHXABMQXSJQ-FXQIFTODSA-N Arg-Ser-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O FRBAHXABMQXSJQ-FXQIFTODSA-N 0.000 description 2
- WCZXPVPHUMYLMS-VEVYYDQMSA-N Arg-Thr-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O WCZXPVPHUMYLMS-VEVYYDQMSA-N 0.000 description 2
- UZSQXCMNUPKLCC-FJXKBIBVSA-N Arg-Thr-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O UZSQXCMNUPKLCC-FJXKBIBVSA-N 0.000 description 2
- UVTGNSWSRSCPLP-UHFFFAOYSA-N Arg-Tyr Natural products NC(CCNC(=N)N)C(=O)NC(Cc1ccc(O)cc1)C(=O)O UVTGNSWSRSCPLP-UHFFFAOYSA-N 0.000 description 2
- CNBIWSCSSCAINS-UFYCRDLUSA-N Arg-Tyr-Tyr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CNBIWSCSSCAINS-UFYCRDLUSA-N 0.000 description 2
- VYZBPPBKFCHCIS-WPRPVWTQSA-N Arg-Val-Gly Chemical compound OC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCN=C(N)N VYZBPPBKFCHCIS-WPRPVWTQSA-N 0.000 description 2
- SUMJNGAMIQSNGX-TUAOUCFPSA-N Arg-Val-Pro Chemical compound CC(C)[C@H](NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N1CCC[C@@H]1C(O)=O SUMJNGAMIQSNGX-TUAOUCFPSA-N 0.000 description 2
- CPTXATAOUQJQRO-GUBZILKMSA-N Arg-Val-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O CPTXATAOUQJQRO-GUBZILKMSA-N 0.000 description 2
- HCAUEJAQCXVQQM-ACZMJKKPSA-N Asn-Glu-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HCAUEJAQCXVQQM-ACZMJKKPSA-N 0.000 description 2
- BKZFBJYIVSBXCO-KKUMJFAQSA-N Asn-Phe-His Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CNC=N1)C(O)=O BKZFBJYIVSBXCO-KKUMJFAQSA-N 0.000 description 2
- UXHYOWXTJLBEPG-GSSVUCPTSA-N Asn-Thr-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UXHYOWXTJLBEPG-GSSVUCPTSA-N 0.000 description 2
- QUCCLIXMVPIVOB-BZSNNMDCSA-N Asn-Tyr-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)N QUCCLIXMVPIVOB-BZSNNMDCSA-N 0.000 description 2
- AECPDLSSUMDUAA-ZKWXMUAHSA-N Asn-Val-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)N)N AECPDLSSUMDUAA-ZKWXMUAHSA-N 0.000 description 2
- NJIKKGUVGUBICV-ZLUOBGJFSA-N Asp-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O NJIKKGUVGUBICV-ZLUOBGJFSA-N 0.000 description 2
- XYBJLTKSGFBLCS-QXEWZRGKSA-N Asp-Arg-Val Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC(O)=O XYBJLTKSGFBLCS-QXEWZRGKSA-N 0.000 description 2
- WCFCYFDBMNFSPA-ACZMJKKPSA-N Asp-Asp-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(O)=O WCFCYFDBMNFSPA-ACZMJKKPSA-N 0.000 description 2
- PXLNPFOJZQMXAT-BYULHYEWSA-N Asp-Asp-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(O)=O PXLNPFOJZQMXAT-BYULHYEWSA-N 0.000 description 2
- ZEDBMCPXPIYJLW-XHNCKOQMSA-N Asp-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)N)C(=O)O ZEDBMCPXPIYJLW-XHNCKOQMSA-N 0.000 description 2
- JUWZKMBALYLZCK-WHFBIAKZSA-N Asp-Gly-Asn Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O JUWZKMBALYLZCK-WHFBIAKZSA-N 0.000 description 2
- QCVXMEHGFUMKCO-YUMQZZPRSA-N Asp-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O QCVXMEHGFUMKCO-YUMQZZPRSA-N 0.000 description 2
- POTCZYQVVNXUIG-BQBZGAKWSA-N Asp-Gly-Pro Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O POTCZYQVVNXUIG-BQBZGAKWSA-N 0.000 description 2
- PAYPSKIBMDHZPI-CIUDSAMLSA-N Asp-Leu-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O PAYPSKIBMDHZPI-CIUDSAMLSA-N 0.000 description 2
- ORRJQLIATJDMQM-HJGDQZAQSA-N Asp-Leu-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O ORRJQLIATJDMQM-HJGDQZAQSA-N 0.000 description 2
- NZWDWXSWUQCNMG-GARJFASQSA-N Asp-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)N)C(=O)O NZWDWXSWUQCNMG-GARJFASQSA-N 0.000 description 2
- DONWIPDSZZJHHK-HJGDQZAQSA-N Asp-Lys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)N)O DONWIPDSZZJHHK-HJGDQZAQSA-N 0.000 description 2
- LIJXJYGRSRWLCJ-IHRRRGAJSA-N Asp-Phe-Arg Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O LIJXJYGRSRWLCJ-IHRRRGAJSA-N 0.000 description 2
- KOWYNSKRPUWSFG-IHPCNDPISA-N Asp-Phe-Trp Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)NC(=O)[C@H](CC(=O)O)N KOWYNSKRPUWSFG-IHPCNDPISA-N 0.000 description 2
- XYPJXLLXNSAWHZ-SRVKXCTJSA-N Asp-Ser-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O XYPJXLLXNSAWHZ-SRVKXCTJSA-N 0.000 description 2
- JSHWXQIZOCVWIA-ZKWXMUAHSA-N Asp-Ser-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O JSHWXQIZOCVWIA-ZKWXMUAHSA-N 0.000 description 2
- NTQDELBZOMWXRS-IWGUZYHVSA-N Asp-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(O)=O NTQDELBZOMWXRS-IWGUZYHVSA-N 0.000 description 2
- GCACQYDBDHRVGE-LKXGYXEUSA-N Asp-Thr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](N)CC(O)=O GCACQYDBDHRVGE-LKXGYXEUSA-N 0.000 description 2
- ITGFVUYOLWBPQW-KKHAAJSZSA-N Asp-Thr-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O ITGFVUYOLWBPQW-KKHAAJSZSA-N 0.000 description 2
- WOKXEQLPBLLWHC-IHRRRGAJSA-N Asp-Tyr-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 WOKXEQLPBLLWHC-IHRRRGAJSA-N 0.000 description 2
- SQIARYGNVQWOSB-BZSNNMDCSA-N Asp-Tyr-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SQIARYGNVQWOSB-BZSNNMDCSA-N 0.000 description 2
- RGTVXXNMOGHRAY-WDSKDSINSA-N Cys-Arg Chemical compound SC[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N RGTVXXNMOGHRAY-WDSKDSINSA-N 0.000 description 2
- QDFBJJABJKOLTD-FXQIFTODSA-N Cys-Asn-Arg Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QDFBJJABJKOLTD-FXQIFTODSA-N 0.000 description 2
- ZJBWJHQDOIMVLM-WHFBIAKZSA-N Cys-Cys-Gly Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(=O)NCC(O)=O ZJBWJHQDOIMVLM-WHFBIAKZSA-N 0.000 description 2
- JDHMXPSXWMPYQZ-AAEUAGOBSA-N Cys-Gly-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CS)N JDHMXPSXWMPYQZ-AAEUAGOBSA-N 0.000 description 2
- IDFVDSBJNMPBSX-SRVKXCTJSA-N Cys-Lys-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O IDFVDSBJNMPBSX-SRVKXCTJSA-N 0.000 description 2
- CNAMJJOZGXPDHW-IHRRRGAJSA-N Cys-Pro-Phe Chemical compound N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O CNAMJJOZGXPDHW-IHRRRGAJSA-N 0.000 description 2
- IZJLAQMWJHCHTN-BPUTZDHNSA-N Cys-Trp-Arg Chemical compound N[C@@H](CS)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O IZJLAQMWJHCHTN-BPUTZDHNSA-N 0.000 description 2
- FNXOZWPPOJRBRE-XGEHTFHBSA-N Cys-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CS)N)O FNXOZWPPOJRBRE-XGEHTFHBSA-N 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- KKCUFHUTMKQQCF-SRVKXCTJSA-N Glu-Arg-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O KKCUFHUTMKQQCF-SRVKXCTJSA-N 0.000 description 2
- YKLNMGJYMNPBCP-ACZMJKKPSA-N Glu-Asn-Asp Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N YKLNMGJYMNPBCP-ACZMJKKPSA-N 0.000 description 2
- UENPHLAAKDPZQY-XKBZYTNZSA-N Glu-Cys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)O)N)O UENPHLAAKDPZQY-XKBZYTNZSA-N 0.000 description 2
- DVLZZEPUNFEUBW-AVGNSLFASA-N Glu-His-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCC(=O)O)N DVLZZEPUNFEUBW-AVGNSLFASA-N 0.000 description 2
- MWMJCGBSIORNCD-AVGNSLFASA-N Glu-Leu-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O MWMJCGBSIORNCD-AVGNSLFASA-N 0.000 description 2
- TWYFJOHWGCCRIR-DCAQKATOSA-N Glu-Pro-Arg Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O TWYFJOHWGCCRIR-DCAQKATOSA-N 0.000 description 2
- JWNZHMSRZXXGTM-XKBZYTNZSA-N Glu-Ser-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JWNZHMSRZXXGTM-XKBZYTNZSA-N 0.000 description 2
- TZXOPHFCAATANZ-QEJZJMRPSA-N Glu-Ser-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)N TZXOPHFCAATANZ-QEJZJMRPSA-N 0.000 description 2
- WXONSNSSBYQGNN-AVGNSLFASA-N Glu-Ser-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O WXONSNSSBYQGNN-AVGNSLFASA-N 0.000 description 2
- GPSHCSTUYOQPAI-JHEQGTHGSA-N Glu-Thr-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O GPSHCSTUYOQPAI-JHEQGTHGSA-N 0.000 description 2
- KIEICAOUSNYOLM-NRPADANISA-N Glu-Val-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O KIEICAOUSNYOLM-NRPADANISA-N 0.000 description 2
- LZEUDRYSAZAJIO-AUTRQRHGSA-N Glu-Val-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O LZEUDRYSAZAJIO-AUTRQRHGSA-N 0.000 description 2
- UGVQELHRNUDMAA-BYPYZUCNSA-N Gly-Ala-Gly Chemical compound [NH3+]CC(=O)N[C@@H](C)C(=O)NCC([O-])=O UGVQELHRNUDMAA-BYPYZUCNSA-N 0.000 description 2
- DTPOVRRYXPJJAZ-FJXKBIBVSA-N Gly-Arg-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N DTPOVRRYXPJJAZ-FJXKBIBVSA-N 0.000 description 2
- FMNHBTKMRFVGRO-FOHZUACHSA-N Gly-Asn-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CN FMNHBTKMRFVGRO-FOHZUACHSA-N 0.000 description 2
- CUYLIWAAAYJKJH-RYUDHWBXSA-N Gly-Glu-Tyr Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CUYLIWAAAYJKJH-RYUDHWBXSA-N 0.000 description 2
- KMSGYZQRXPUKGI-BYPYZUCNSA-N Gly-Gly-Asn Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC(N)=O KMSGYZQRXPUKGI-BYPYZUCNSA-N 0.000 description 2
- UFPXDFOYHVEIPI-BYPYZUCNSA-N Gly-Gly-Asp Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O UFPXDFOYHVEIPI-BYPYZUCNSA-N 0.000 description 2
- OLPPXYMMIARYAL-QMMMGPOBSA-N Gly-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)CN OLPPXYMMIARYAL-QMMMGPOBSA-N 0.000 description 2
- YFGONBOFGGWKKY-VHSXEESVSA-N Gly-His-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)CN)C(=O)O YFGONBOFGGWKKY-VHSXEESVSA-N 0.000 description 2
- PAWIVEIWWYGBAM-YUMQZZPRSA-N Gly-Leu-Ala Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O PAWIVEIWWYGBAM-YUMQZZPRSA-N 0.000 description 2
- NSTUFLGQJCOCDL-UWVGGRQHSA-N Gly-Leu-Arg Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N NSTUFLGQJCOCDL-UWVGGRQHSA-N 0.000 description 2
- UHPAZODVFFYEEL-QWRGUYRKSA-N Gly-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN UHPAZODVFFYEEL-QWRGUYRKSA-N 0.000 description 2
- LHYJCVCQPWRMKZ-WEDXCCLWSA-N Gly-Leu-Thr Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LHYJCVCQPWRMKZ-WEDXCCLWSA-N 0.000 description 2
- MIIVFRCYJABHTQ-ONGXEEELSA-N Gly-Leu-Val Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O MIIVFRCYJABHTQ-ONGXEEELSA-N 0.000 description 2
- VBOBNHSVQKKTOT-YUMQZZPRSA-N Gly-Lys-Ala Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O VBOBNHSVQKKTOT-YUMQZZPRSA-N 0.000 description 2
- VLIJYPMATZSOLL-YUMQZZPRSA-N Gly-Lys-Cys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)CN VLIJYPMATZSOLL-YUMQZZPRSA-N 0.000 description 2
- CVFOYJJOZYYEPE-KBPBESRZSA-N Gly-Lys-Tyr Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CVFOYJJOZYYEPE-KBPBESRZSA-N 0.000 description 2
- OCPPBNKYGYSLOE-IUCAKERBSA-N Gly-Pro-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN OCPPBNKYGYSLOE-IUCAKERBSA-N 0.000 description 2
- BMWFDYIYBAFROD-WPRPVWTQSA-N Gly-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN BMWFDYIYBAFROD-WPRPVWTQSA-N 0.000 description 2
- IRJWAYCXIYUHQE-WHFBIAKZSA-N Gly-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)CN IRJWAYCXIYUHQE-WHFBIAKZSA-N 0.000 description 2
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 2
- WCORRBXVISTKQL-WHFBIAKZSA-N Gly-Ser-Ser Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WCORRBXVISTKQL-WHFBIAKZSA-N 0.000 description 2
- FFJQHWKSGAWSTJ-BFHQHQDPSA-N Gly-Thr-Ala Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O FFJQHWKSGAWSTJ-BFHQHQDPSA-N 0.000 description 2
- CUVBTVWFVIIDOC-YEPSODPASA-N Gly-Thr-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)CN CUVBTVWFVIIDOC-YEPSODPASA-N 0.000 description 2
- UMBDRSMLCUYIRI-DVJZZOLTSA-N Gly-Trp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)CN)O UMBDRSMLCUYIRI-DVJZZOLTSA-N 0.000 description 2
- YTKOTXRIWQHSAZ-GUBZILKMSA-N His-Glu-Cys Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N YTKOTXRIWQHSAZ-GUBZILKMSA-N 0.000 description 2
- ORZGPQXISSXQGW-IHRRRGAJSA-N His-His-Val Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C(C)C)C(O)=O ORZGPQXISSXQGW-IHRRRGAJSA-N 0.000 description 2
- CCUSLCQWVMWTIS-IXOXFDKPSA-N His-Thr-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O CCUSLCQWVMWTIS-IXOXFDKPSA-N 0.000 description 2
- LPBWRHRHEIYAIP-KKUMJFAQSA-N His-Tyr-Asp Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O LPBWRHRHEIYAIP-KKUMJFAQSA-N 0.000 description 2
- 101710146024 Horcolin Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 2
- SENJXOPIZNYLHU-UHFFFAOYSA-N L-leucyl-L-arginine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-UHFFFAOYSA-N 0.000 description 2
- KFKWRHQBZQICHA-STQMWFEESA-N L-leucyl-L-phenylalanine Natural products CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KFKWRHQBZQICHA-STQMWFEESA-N 0.000 description 2
- 101710189395 Lectin Proteins 0.000 description 2
- 241000255777 Lepidoptera Species 0.000 description 2
- 241000880493 Leptailurus serval Species 0.000 description 2
- LJHGALIOHLRRQN-DCAQKATOSA-N Leu-Ala-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N LJHGALIOHLRRQN-DCAQKATOSA-N 0.000 description 2
- CZCSUZMIRKFFFA-CIUDSAMLSA-N Leu-Ala-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O CZCSUZMIRKFFFA-CIUDSAMLSA-N 0.000 description 2
- CUXRXAIAVYLVFD-ULQDDVLXSA-N Leu-Arg-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CUXRXAIAVYLVFD-ULQDDVLXSA-N 0.000 description 2
- VCSBGUACOYUIGD-CIUDSAMLSA-N Leu-Asn-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O VCSBGUACOYUIGD-CIUDSAMLSA-N 0.000 description 2
- WGNOPSQMIQERPK-GARJFASQSA-N Leu-Asn-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N WGNOPSQMIQERPK-GARJFASQSA-N 0.000 description 2
- WGNOPSQMIQERPK-UHFFFAOYSA-N Leu-Asn-Pro Natural products CC(C)CC(N)C(=O)NC(CC(=O)N)C(=O)N1CCCC1C(=O)O WGNOPSQMIQERPK-UHFFFAOYSA-N 0.000 description 2
- TWQIYNGNYNJUFM-NHCYSSNCSA-N Leu-Asn-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O TWQIYNGNYNJUFM-NHCYSSNCSA-N 0.000 description 2
- RVVBWTWPNFDYBE-SRVKXCTJSA-N Leu-Glu-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O RVVBWTWPNFDYBE-SRVKXCTJSA-N 0.000 description 2
- IAJFFZORSWOZPQ-SRVKXCTJSA-N Leu-Leu-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O IAJFFZORSWOZPQ-SRVKXCTJSA-N 0.000 description 2
- KYIIALJHAOIAHF-KKUMJFAQSA-N Leu-Leu-His Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 KYIIALJHAOIAHF-KKUMJFAQSA-N 0.000 description 2
- IEWBEPKLKUXQBU-VOAKCMCISA-N Leu-Leu-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IEWBEPKLKUXQBU-VOAKCMCISA-N 0.000 description 2
- WXUOJXIGOPMDJM-SRVKXCTJSA-N Leu-Lys-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O WXUOJXIGOPMDJM-SRVKXCTJSA-N 0.000 description 2
- OVZLLFONXILPDZ-VOAKCMCISA-N Leu-Lys-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OVZLLFONXILPDZ-VOAKCMCISA-N 0.000 description 2
- NTISAKGPIGTIJJ-IUCAKERBSA-N Leu-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(C)C NTISAKGPIGTIJJ-IUCAKERBSA-N 0.000 description 2
- WXDRGWBQZIMJDE-ULQDDVLXSA-N Leu-Phe-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(O)=O WXDRGWBQZIMJDE-ULQDDVLXSA-N 0.000 description 2
- MVVSHHJKJRZVNY-ACRUOGEOSA-N Leu-Phe-Tyr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MVVSHHJKJRZVNY-ACRUOGEOSA-N 0.000 description 2
- PWPBLZXWFXJFHE-RHYQMDGZSA-N Leu-Pro-Thr Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O PWPBLZXWFXJFHE-RHYQMDGZSA-N 0.000 description 2
- XOWMDXHFSBCAKQ-SRVKXCTJSA-N Leu-Ser-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(C)C XOWMDXHFSBCAKQ-SRVKXCTJSA-N 0.000 description 2
- BRTVHXHCUSXYRI-CIUDSAMLSA-N Leu-Ser-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O BRTVHXHCUSXYRI-CIUDSAMLSA-N 0.000 description 2
- QWWPYKKLXWOITQ-VOAKCMCISA-N Leu-Thr-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(C)C QWWPYKKLXWOITQ-VOAKCMCISA-N 0.000 description 2
- ILDSIMPXNFWKLH-KATARQTJSA-N Leu-Thr-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O ILDSIMPXNFWKLH-KATARQTJSA-N 0.000 description 2
- AIQWYVFNBNNOLU-RHYQMDGZSA-N Leu-Thr-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O AIQWYVFNBNNOLU-RHYQMDGZSA-N 0.000 description 2
- FDBTVENULFNTAL-XQQFMLRXSA-N Leu-Val-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N FDBTVENULFNTAL-XQQFMLRXSA-N 0.000 description 2
- VKVDRTGWLVZJOM-DCAQKATOSA-N Leu-Val-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O VKVDRTGWLVZJOM-DCAQKATOSA-N 0.000 description 2
- QQYRCUXKLDGCQN-SRVKXCTJSA-N Lys-Cys-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CCCCN)N QQYRCUXKLDGCQN-SRVKXCTJSA-N 0.000 description 2
- LCMWVZLBCUVDAZ-IUCAKERBSA-N Lys-Gly-Glu Chemical compound [NH3+]CCCC[C@H]([NH3+])C(=O)NCC(=O)N[C@H](C([O-])=O)CCC([O-])=O LCMWVZLBCUVDAZ-IUCAKERBSA-N 0.000 description 2
- XOQMURBBIXRRCR-SRVKXCTJSA-N Lys-Lys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN XOQMURBBIXRRCR-SRVKXCTJSA-N 0.000 description 2
- UDXSLGLHFUBRRM-OEAJRASXSA-N Lys-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCCCN)N)O UDXSLGLHFUBRRM-OEAJRASXSA-N 0.000 description 2
- HKXSZKJMDBHOTG-CIUDSAMLSA-N Lys-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCCN HKXSZKJMDBHOTG-CIUDSAMLSA-N 0.000 description 2
- MGKFCQFVPKOWOL-CIUDSAMLSA-N Lys-Ser-Asp Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)O)N MGKFCQFVPKOWOL-CIUDSAMLSA-N 0.000 description 2
- IOQWIOPSKJOEKI-SRVKXCTJSA-N Lys-Ser-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O IOQWIOPSKJOEKI-SRVKXCTJSA-N 0.000 description 2
- 101710179758 Mannose-specific lectin Proteins 0.000 description 2
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 2
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 2
- GAELMDJMQDUDLJ-BQBZGAKWSA-N Met-Ala-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O GAELMDJMQDUDLJ-BQBZGAKWSA-N 0.000 description 2
- DNDVVILEHVMWIS-LPEHRKFASA-N Met-Asp-Pro Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N DNDVVILEHVMWIS-LPEHRKFASA-N 0.000 description 2
- OGAZPKJHHZPYFK-GARJFASQSA-N Met-Glu-Pro Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N OGAZPKJHHZPYFK-GARJFASQSA-N 0.000 description 2
- OOSPRDCGTLQLBP-NHCYSSNCSA-N Met-Glu-Val Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O OOSPRDCGTLQLBP-NHCYSSNCSA-N 0.000 description 2
- DGNZGCQSVGGYJS-BQBZGAKWSA-N Met-Gly-Asp Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O DGNZGCQSVGGYJS-BQBZGAKWSA-N 0.000 description 2
- AFFKUNVPPLQUGA-DCAQKATOSA-N Met-Leu-Ala Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O AFFKUNVPPLQUGA-DCAQKATOSA-N 0.000 description 2
- HZVXPUHLTZRQEL-UWVGGRQHSA-N Met-Leu-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O HZVXPUHLTZRQEL-UWVGGRQHSA-N 0.000 description 2
- KMSMNUFBNCHMII-IHRRRGAJSA-N Met-Leu-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCCN KMSMNUFBNCHMII-IHRRRGAJSA-N 0.000 description 2
- MIXPUVSPPOWTCR-FXQIFTODSA-N Met-Ser-Ser Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MIXPUVSPPOWTCR-FXQIFTODSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101100508818 Mus musculus Inpp5k gene Proteins 0.000 description 2
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 2
- MDHZEOMXGNBSIL-DLOVCJGASA-N Phe-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N MDHZEOMXGNBSIL-DLOVCJGASA-N 0.000 description 2
- YQNBKXUTWBRQCS-BVSLBCMMSA-N Phe-Arg-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=CC=C1 YQNBKXUTWBRQCS-BVSLBCMMSA-N 0.000 description 2
- CSYVXYQDIVCQNU-QWRGUYRKSA-N Phe-Asp-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O CSYVXYQDIVCQNU-QWRGUYRKSA-N 0.000 description 2
- RIYZXJVARWJLKS-KKUMJFAQSA-N Phe-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 RIYZXJVARWJLKS-KKUMJFAQSA-N 0.000 description 2
- DJPXNKUDJKGQEE-BZSNNMDCSA-N Phe-Asp-Phe Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O DJPXNKUDJKGQEE-BZSNNMDCSA-N 0.000 description 2
- GZGPMBKUJDRICD-ULQDDVLXSA-N Phe-Pro-His Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@@H](CC3=CN=CN3)C(=O)O GZGPMBKUJDRICD-ULQDDVLXSA-N 0.000 description 2
- XOHJOMKCRLHGCY-UNQGMJICSA-N Phe-Pro-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O XOHJOMKCRLHGCY-UNQGMJICSA-N 0.000 description 2
- QSWKNJAPHQDAAS-MELADBBJSA-N Phe-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O QSWKNJAPHQDAAS-MELADBBJSA-N 0.000 description 2
- LKRUQZQZMXMKEQ-SFJXLCSZSA-N Phe-Trp-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LKRUQZQZMXMKEQ-SFJXLCSZSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ALJGSKMBIUEJOB-FXQIFTODSA-N Pro-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@@H]1CCCN1 ALJGSKMBIUEJOB-FXQIFTODSA-N 0.000 description 2
- WECYCNFPGZLOOU-FXQIFTODSA-N Pro-Asn-Cys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)O WECYCNFPGZLOOU-FXQIFTODSA-N 0.000 description 2
- AIZVVCMAFRREQS-GUBZILKMSA-N Pro-Cys-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AIZVVCMAFRREQS-GUBZILKMSA-N 0.000 description 2
- JUJGNDZIKKQMDJ-IHRRRGAJSA-N Pro-His-His Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CNC=N1)C(O)=O JUJGNDZIKKQMDJ-IHRRRGAJSA-N 0.000 description 2
- XFFIGWGYMUFCCQ-ULQDDVLXSA-N Pro-His-Tyr Chemical compound C1=CC(O)=CC=C1C[C@@H](C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H]1[NH2+]CCC1)CC1=CN=CN1 XFFIGWGYMUFCCQ-ULQDDVLXSA-N 0.000 description 2
- CLJLVCYFABNTHP-DCAQKATOSA-N Pro-Leu-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O CLJLVCYFABNTHP-DCAQKATOSA-N 0.000 description 2
- XQPHBAKJJJZOBX-SRVKXCTJSA-N Pro-Lys-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O XQPHBAKJJJZOBX-SRVKXCTJSA-N 0.000 description 2
- CGSOWZUPLOKYOR-AVGNSLFASA-N Pro-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 CGSOWZUPLOKYOR-AVGNSLFASA-N 0.000 description 2
- GMJDSFYVTAMIBF-FXQIFTODSA-N Pro-Ser-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O GMJDSFYVTAMIBF-FXQIFTODSA-N 0.000 description 2
- FHJQROWZEJFZPO-SRVKXCTJSA-N Pro-Val-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 FHJQROWZEJFZPO-SRVKXCTJSA-N 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 101100366438 Rattus norvegicus Sphkap gene Proteins 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 241000239226 Scorpiones Species 0.000 description 2
- MWMKFWJYRRGXOR-ZLUOBGJFSA-N Ser-Ala-Asn Chemical compound N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)CC(N)=O)C)CO MWMKFWJYRRGXOR-ZLUOBGJFSA-N 0.000 description 2
- BTKUIVBNGBFTTP-WHFBIAKZSA-N Ser-Ala-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(O)=O BTKUIVBNGBFTTP-WHFBIAKZSA-N 0.000 description 2
- WDXYVIIVDIDOSX-DCAQKATOSA-N Ser-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CCCN=C(N)N WDXYVIIVDIDOSX-DCAQKATOSA-N 0.000 description 2
- FIDMVVBUOCMMJG-CIUDSAMLSA-N Ser-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO FIDMVVBUOCMMJG-CIUDSAMLSA-N 0.000 description 2
- TYYBJUYSTWJHGO-ZKWXMUAHSA-N Ser-Asn-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O TYYBJUYSTWJHGO-ZKWXMUAHSA-N 0.000 description 2
- VBKBDLMWICBSCY-IMJSIDKUSA-N Ser-Asp Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O VBKBDLMWICBSCY-IMJSIDKUSA-N 0.000 description 2
- MESDJCNHLZBMEP-ZLUOBGJFSA-N Ser-Asp-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MESDJCNHLZBMEP-ZLUOBGJFSA-N 0.000 description 2
- UQFYNFTYDHUIMI-WHFBIAKZSA-N Ser-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CO UQFYNFTYDHUIMI-WHFBIAKZSA-N 0.000 description 2
- GZFAWAQTEYDKII-YUMQZZPRSA-N Ser-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO GZFAWAQTEYDKII-YUMQZZPRSA-N 0.000 description 2
- QGAHMVHBORDHDC-YUMQZZPRSA-N Ser-His-Gly Chemical compound OC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CN=CN1 QGAHMVHBORDHDC-YUMQZZPRSA-N 0.000 description 2
- NFDYGNFETJVMSE-BQBZGAKWSA-N Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CO NFDYGNFETJVMSE-BQBZGAKWSA-N 0.000 description 2
- XVWDJUROVRQKAE-KKUMJFAQSA-N Ser-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CC1=CC=CC=C1 XVWDJUROVRQKAE-KKUMJFAQSA-N 0.000 description 2
- RWDVVSKYZBNDCO-MELADBBJSA-N Ser-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CO)N)C(=O)O RWDVVSKYZBNDCO-MELADBBJSA-N 0.000 description 2
- MQUZANJDFOQOBX-SRVKXCTJSA-N Ser-Phe-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O MQUZANJDFOQOBX-SRVKXCTJSA-N 0.000 description 2
- FBLNYDYPCLFTSP-IXOXFDKPSA-N Ser-Phe-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O FBLNYDYPCLFTSP-IXOXFDKPSA-N 0.000 description 2
- QMCDMHWAKMUGJE-IHRRRGAJSA-N Ser-Phe-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O QMCDMHWAKMUGJE-IHRRRGAJSA-N 0.000 description 2
- OVQZAFXWIWNYKA-GUBZILKMSA-N Ser-Pro-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CO)N OVQZAFXWIWNYKA-GUBZILKMSA-N 0.000 description 2
- WLJPJRGQRNCIQS-ZLUOBGJFSA-N Ser-Ser-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O WLJPJRGQRNCIQS-ZLUOBGJFSA-N 0.000 description 2
- OLKICIBQRVSQMA-SRVKXCTJSA-N Ser-Ser-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OLKICIBQRVSQMA-SRVKXCTJSA-N 0.000 description 2
- XJDMUQCLVSCRSJ-VZFHVOOUSA-N Ser-Thr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O XJDMUQCLVSCRSJ-VZFHVOOUSA-N 0.000 description 2
- SQHKXWODKJDZRC-LKXGYXEUSA-N Ser-Thr-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O SQHKXWODKJDZRC-LKXGYXEUSA-N 0.000 description 2
- VLMIUSLQONKLDV-HEIBUPTGSA-N Ser-Thr-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VLMIUSLQONKLDV-HEIBUPTGSA-N 0.000 description 2
- PMTWIUBUQRGCSB-FXQIFTODSA-N Ser-Val-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O PMTWIUBUQRGCSB-FXQIFTODSA-N 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- DFTCYYILCSQGIZ-GCJQMDKQSA-N Thr-Ala-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O DFTCYYILCSQGIZ-GCJQMDKQSA-N 0.000 description 2
- NFMPFBCXABPALN-OWLDWWDNSA-N Thr-Ala-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N)O NFMPFBCXABPALN-OWLDWWDNSA-N 0.000 description 2
- LXWZOMSOUAMOIA-JIOCBJNQSA-N Thr-Asn-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N)O LXWZOMSOUAMOIA-JIOCBJNQSA-N 0.000 description 2
- IOWJRKAVLALBQB-IWGUZYHVSA-N Thr-Asp Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O IOWJRKAVLALBQB-IWGUZYHVSA-N 0.000 description 2
- ONNSECRQFSTMCC-XKBZYTNZSA-N Thr-Glu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O ONNSECRQFSTMCC-XKBZYTNZSA-N 0.000 description 2
- BIYXEUAFGLTAEM-WUJLRWPWSA-N Thr-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(O)=O BIYXEUAFGLTAEM-WUJLRWPWSA-N 0.000 description 2
- XFTYVCHLARBHBQ-FOHZUACHSA-N Thr-Gly-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O XFTYVCHLARBHBQ-FOHZUACHSA-N 0.000 description 2
- WXVIGTAUZBUDPZ-DTLFHODZSA-N Thr-His Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 WXVIGTAUZBUDPZ-DTLFHODZSA-N 0.000 description 2
- KZURUCDWKDEAFZ-XVSYOHENSA-N Thr-Phe-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O KZURUCDWKDEAFZ-XVSYOHENSA-N 0.000 description 2
- GYUUYCIXELGTJS-MEYUZBJRSA-N Thr-Phe-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N)O GYUUYCIXELGTJS-MEYUZBJRSA-N 0.000 description 2
- DEGCBBCMYWNJNA-RHYQMDGZSA-N Thr-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)[C@@H](C)O DEGCBBCMYWNJNA-RHYQMDGZSA-N 0.000 description 2
- STUAPCLEDMKXKL-LKXGYXEUSA-N Thr-Ser-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O STUAPCLEDMKXKL-LKXGYXEUSA-N 0.000 description 2
- NBIIPOKZPUGATB-BWBBJGPYSA-N Thr-Ser-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N)O NBIIPOKZPUGATB-BWBBJGPYSA-N 0.000 description 2
- BBPCSGKKPJUYRB-UVOCVTCTSA-N Thr-Thr-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O BBPCSGKKPJUYRB-UVOCVTCTSA-N 0.000 description 2
- COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 2
- BEZTUFWTPVOROW-KJEVXHAQSA-N Thr-Tyr-Arg Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N)O BEZTUFWTPVOROW-KJEVXHAQSA-N 0.000 description 2
- PWONLXBUSVIZPH-RHYQMDGZSA-N Thr-Val-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N)O PWONLXBUSVIZPH-RHYQMDGZSA-N 0.000 description 2
- RNFZZCMCRDFNAE-WFBYXXMGSA-N Trp-Asn-Ala Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O RNFZZCMCRDFNAE-WFBYXXMGSA-N 0.000 description 2
- WQYPAGQDXAJNED-AAEUAGOBSA-N Trp-Cys-Gly Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)O)N WQYPAGQDXAJNED-AAEUAGOBSA-N 0.000 description 2
- HJXOFWKCWLHYIJ-SZMVWBNQSA-N Trp-Lys-Glu Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O HJXOFWKCWLHYIJ-SZMVWBNQSA-N 0.000 description 2
- NJNCVQYFNKZMAH-JYBASQMISA-N Trp-Thr-Cys Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CS)C(O)=O)=CNC2=C1 NJNCVQYFNKZMAH-JYBASQMISA-N 0.000 description 2
- DXYWRYQRKPIGGU-BPNCWPANSA-N Tyr-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 DXYWRYQRKPIGGU-BPNCWPANSA-N 0.000 description 2
- AKFLVKKWVZMFOT-IHRRRGAJSA-N Tyr-Arg-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O AKFLVKKWVZMFOT-IHRRRGAJSA-N 0.000 description 2
- CYDVHRFXDMDMGX-KKUMJFAQSA-N Tyr-Asn-His Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N)O CYDVHRFXDMDMGX-KKUMJFAQSA-N 0.000 description 2
- UABYBEBXFFNCIR-YDHLFZDLSA-N Tyr-Asp-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O UABYBEBXFFNCIR-YDHLFZDLSA-N 0.000 description 2
- CGDZGRLRXPNCOC-SRVKXCTJSA-N Tyr-Cys-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 CGDZGRLRXPNCOC-SRVKXCTJSA-N 0.000 description 2
- XQYHLZNPOTXRMQ-KKUMJFAQSA-N Tyr-Glu-Arg Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O XQYHLZNPOTXRMQ-KKUMJFAQSA-N 0.000 description 2
- QAYSODICXVZUIA-WLTAIBSBSA-N Tyr-Gly-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O QAYSODICXVZUIA-WLTAIBSBSA-N 0.000 description 2
- GULIUBBXCYPDJU-CQDKDKBSSA-N Tyr-Leu-Ala Chemical compound [O-]C(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CC1=CC=C(O)C=C1 GULIUBBXCYPDJU-CQDKDKBSSA-N 0.000 description 2
- CDKZJGMPZHPAJC-ULQDDVLXSA-N Tyr-Leu-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 CDKZJGMPZHPAJC-ULQDDVLXSA-N 0.000 description 2
- UPODKYBYUBTWSV-BZSNNMDCSA-N Tyr-Phe-Cys Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CS)C(O)=O)C1=CC=C(O)C=C1 UPODKYBYUBTWSV-BZSNNMDCSA-N 0.000 description 2
- ZZDYJFVIKVSUFA-WLTAIBSBSA-N Tyr-Thr-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O ZZDYJFVIKVSUFA-WLTAIBSBSA-N 0.000 description 2
- CLEGSEJVGBYZBJ-MEYUZBJRSA-N Tyr-Thr-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 CLEGSEJVGBYZBJ-MEYUZBJRSA-N 0.000 description 2
- ABZWHLRQBSBPTO-RNXOBYDBSA-N Tyr-Trp-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CC4=CC=C(C=C4)O)N ABZWHLRQBSBPTO-RNXOBYDBSA-N 0.000 description 2
- ASQFIHTXXMFENG-XPUUQOCRSA-N Val-Ala-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O ASQFIHTXXMFENG-XPUUQOCRSA-N 0.000 description 2
- SLLKXDSRVAOREO-KZVJFYERSA-N Val-Ala-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)N)O SLLKXDSRVAOREO-KZVJFYERSA-N 0.000 description 2
- QPZMOUMNTGTEFR-ZKWXMUAHSA-N Val-Asn-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)N QPZMOUMNTGTEFR-ZKWXMUAHSA-N 0.000 description 2
- DDNIHOWRDOXXPF-NGZCFLSTSA-N Val-Asp-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N DDNIHOWRDOXXPF-NGZCFLSTSA-N 0.000 description 2
- SCBITHMBEJNRHC-LSJOCFKGSA-N Val-Asp-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)O)N SCBITHMBEJNRHC-LSJOCFKGSA-N 0.000 description 2
- FEFZWCSXEMVSPO-LSJOCFKGSA-N Val-His-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](C)C(O)=O FEFZWCSXEMVSPO-LSJOCFKGSA-N 0.000 description 2
- SYSWVVCYSXBVJG-RHYQMDGZSA-N Val-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N)O SYSWVVCYSXBVJG-RHYQMDGZSA-N 0.000 description 2
- WDIWOIRFNMLNKO-ULQDDVLXSA-N Val-Leu-Tyr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 WDIWOIRFNMLNKO-ULQDDVLXSA-N 0.000 description 2
- YMTOEGGOCHVGEH-IHRRRGAJSA-N Val-Lys-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O YMTOEGGOCHVGEH-IHRRRGAJSA-N 0.000 description 2
- HPANGHISDXDUQY-ULQDDVLXSA-N Val-Lys-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N HPANGHISDXDUQY-ULQDDVLXSA-N 0.000 description 2
- CKTMJBPRVQWPHU-JSGCOSHPSA-N Val-Phe-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)O)N CKTMJBPRVQWPHU-JSGCOSHPSA-N 0.000 description 2
- YKNOJPJWNVHORX-UNQGMJICSA-N Val-Phe-Thr Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(O)=O)CC1=CC=CC=C1 YKNOJPJWNVHORX-UNQGMJICSA-N 0.000 description 2
- ZXYPHBKIZLAQTL-QXEWZRGKSA-N Val-Pro-Asp Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)O)N ZXYPHBKIZLAQTL-QXEWZRGKSA-N 0.000 description 2
- KSFXWENSJABBFI-ZKWXMUAHSA-N Val-Ser-Asn Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O KSFXWENSJABBFI-ZKWXMUAHSA-N 0.000 description 2
- VHIZXDZMTDVFGX-DCAQKATOSA-N Val-Ser-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N VHIZXDZMTDVFGX-DCAQKATOSA-N 0.000 description 2
- GBIUHAYJGWVNLN-AEJSXWLSSA-N Val-Ser-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N GBIUHAYJGWVNLN-AEJSXWLSSA-N 0.000 description 2
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 2
- CEKSLIVSNNGOKH-KZVJFYERSA-N Val-Thr-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](C(C)C)N)O CEKSLIVSNNGOKH-KZVJFYERSA-N 0.000 description 2
- MNSSBIHFEUUXNW-RCWTZXSCSA-N Val-Thr-Arg Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N MNSSBIHFEUUXNW-RCWTZXSCSA-N 0.000 description 2
- DLRZGNXCXUGIDG-KKHAAJSZSA-N Val-Thr-Asp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N)O DLRZGNXCXUGIDG-KKHAAJSZSA-N 0.000 description 2
- PDDJTOSAVNRJRH-UNQGMJICSA-N Val-Thr-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](C(C)C)N)O PDDJTOSAVNRJRH-UNQGMJICSA-N 0.000 description 2
- LLJLBRRXKZTTRD-GUBZILKMSA-N Val-Val-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)O)N LLJLBRRXKZTTRD-GUBZILKMSA-N 0.000 description 2
- 239000000910 agglutinin Substances 0.000 description 2
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 description 2
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 2
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 2
- 108010047495 alanylglycine Proteins 0.000 description 2
- 108010087924 alanylproline Proteins 0.000 description 2
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 2
- 108010043240 arginyl-leucyl-glycine Proteins 0.000 description 2
- 108010068380 arginylarginine Proteins 0.000 description 2
- 108010060035 arginylproline Proteins 0.000 description 2
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 2
- 108010047857 aspartylglycine Proteins 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000012761 co-transfection Methods 0.000 description 2
- 108010060199 cysteinylproline Proteins 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 108010057083 glutamyl-aspartyl-leucine Proteins 0.000 description 2
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 2
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 2
- 108010027668 glycyl-alanyl-valine Proteins 0.000 description 2
- 108010072405 glycyl-aspartyl-glycine Proteins 0.000 description 2
- 108010078326 glycyl-glycyl-valine Proteins 0.000 description 2
- 108010082286 glycyl-seryl-alanine Proteins 0.000 description 2
- 108010089804 glycyl-threonine Proteins 0.000 description 2
- 108010015792 glycyllysine Proteins 0.000 description 2
- 108010040030 histidinoalanine Proteins 0.000 description 2
- 108010018006 histidylserine Proteins 0.000 description 2
- 101150066555 lacZ gene Proteins 0.000 description 2
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 2
- 108010034529 leucyl-lysine Proteins 0.000 description 2
- 108010044056 leucyl-phenylalanine Proteins 0.000 description 2
- 108010000761 leucylarginine Proteins 0.000 description 2
- 108010091871 leucylmethionine Proteins 0.000 description 2
- 108010017391 lysylvaline Proteins 0.000 description 2
- 108010056582 methionylglutamic acid Proteins 0.000 description 2
- 108010085203 methionylmethionine Proteins 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 108010012581 phenylalanylglutamate Proteins 0.000 description 2
- 108010051242 phenylalanylserine Proteins 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108010031719 prolyl-serine Proteins 0.000 description 2
- 108010070643 prolylglutamic acid Proteins 0.000 description 2
- 108010090894 prolylleucine Proteins 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 108010026333 seryl-proline Proteins 0.000 description 2
- 108010007375 seryl-seryl-seryl-arginine Proteins 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 101150003509 tag gene Proteins 0.000 description 2
- 108010033670 threonyl-aspartyl-tyrosine Proteins 0.000 description 2
- 108010035534 tyrosyl-leucyl-alanine Proteins 0.000 description 2
- 108010020532 tyrosyl-proline Proteins 0.000 description 2
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 1
- XBJPSVQFCQFGDC-WSCOIBMGSA-K 2-[4-[2-[[(2R)-1-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-[[(1S,2R)-1-carboxy-2-hydroxypropyl]carbamoyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]-7,10-bis(carboxylatomethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate gallium-68(3+) Chemical compound [68Ga+3].C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](Cc2ccccc2)NC(=O)CN2CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(O)=O XBJPSVQFCQFGDC-WSCOIBMGSA-K 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- XAGIMRPOEJSYER-CIUDSAMLSA-N Ala-Cys-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)O)N XAGIMRPOEJSYER-CIUDSAMLSA-N 0.000 description 1
- AUZAXCPWMDBWEE-HJGDQZAQSA-N Arg-Thr-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O AUZAXCPWMDBWEE-HJGDQZAQSA-N 0.000 description 1
- NVPHRWNWTKYIST-BPNCWPANSA-N Arg-Tyr-Ala Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CC=C(O)C=C1 NVPHRWNWTKYIST-BPNCWPANSA-N 0.000 description 1
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100263837 Bovine ephemeral fever virus (strain BB7721) beta gene Proteins 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- SBDVXRYCOIEYNV-YUMQZZPRSA-N Cys-His-Gly Chemical compound C1=C(NC=N1)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CS)N SBDVXRYCOIEYNV-YUMQZZPRSA-N 0.000 description 1
- 241000537219 Deltabaculovirus Species 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 101100316840 Enterobacteria phage P4 Beta gene Proteins 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 241001200922 Gagata Species 0.000 description 1
- 101710111383 Gene 64 protein Proteins 0.000 description 1
- CYHBMLHCQXXCCT-AVGNSLFASA-N Glu-Asp-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CYHBMLHCQXXCCT-AVGNSLFASA-N 0.000 description 1
- OVSKVOOUFAKODB-UWVGGRQHSA-N Gly-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N OVSKVOOUFAKODB-UWVGGRQHSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- AASLOGQZZKZWKH-SRVKXCTJSA-N His-Cys-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N AASLOGQZZKZWKH-SRVKXCTJSA-N 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- DZQMXBALGUHGJT-GUBZILKMSA-N Leu-Glu-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O DZQMXBALGUHGJT-GUBZILKMSA-N 0.000 description 1
- ZOKVLMBYDSIDKG-CSMHCCOUSA-N Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN ZOKVLMBYDSIDKG-CSMHCCOUSA-N 0.000 description 1
- CAVRAQIDHUPECU-UVOCVTCTSA-N Lys-Thr-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAVRAQIDHUPECU-UVOCVTCTSA-N 0.000 description 1
- 241000275031 Nica Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 241000710778 Pestivirus Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- MOQDPPUMFSMYOM-KKUMJFAQSA-N Ser-His-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CO)N MOQDPPUMFSMYOM-KKUMJFAQSA-N 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- BSNZTJXVDOINSR-JXUBOQSCSA-N Thr-Ala-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O BSNZTJXVDOINSR-JXUBOQSCSA-N 0.000 description 1
- BNGDYRRHRGOPHX-IFFSRLJSSA-N Thr-Glu-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)[C@@H](C)O)C(O)=O BNGDYRRHRGOPHX-IFFSRLJSSA-N 0.000 description 1
- WRQLCVIALDUQEQ-UNQGMJICSA-N Thr-Phe-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O WRQLCVIALDUQEQ-UNQGMJICSA-N 0.000 description 1
- 102000008579 Transposases Human genes 0.000 description 1
- 108010020764 Transposases Proteins 0.000 description 1
- XPKCFQZDQGVJCX-RHYQMDGZSA-N Val-Lys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)N)O XPKCFQZDQGVJCX-RHYQMDGZSA-N 0.000 description 1
- 101710099833 Venom protein Proteins 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 108010070944 alanylhistidine Proteins 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
- 230000000853 biopesticidal effect Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 101150104611 dx gene Proteins 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 101150045064 gp64 gene Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 108010036413 histidylglycine Proteins 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 108700010900 influenza virus proteins Proteins 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000009004 jinqing Substances 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 108010044348 lysyl-glutamyl-aspartic acid Proteins 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 241000701451 unidentified granulovirus Species 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
201006928 九、發明說明: « 【發明所屬之技術領域】 % 本發明涉及-種外源基因之表面呈㈣統特 關於一種泛用型桿狀病毒表面呈現系統。 【先前技術】 桿狀病毒除了是目前有機農業上極具 潛力之生物農藥,是當今工業及醫學上生產重要外源蛋 Ο 白之賴“。桿狀病毒只錢好椎祕,約有_種 2上的無脊椎動物皆是桿狀病毒的宿主,其中多數宿主為 昆蟲,包括鱗翅目、膜翅目、雙翅目及鞘翅目,又以鱗翅 目昆A為桿狀病毒的主要宿主。桿狀病毒分類上可細分為 兩個亞科.真;f干狀病毒亞科(Eubacui〇virjnae)與裸桿^ 病毒亞科(Nudibaculovirinae)’其中該真桿狀病毒亞科又 了細刀為兩個屬顆粒體病毒(grimw/o幻y ; GV) 反枝多肖後病奏 Q nuclear polyhedrosis virus .,ΝΡλ/) ·,矣 〇 中該核多角體病毒含有很強的多角體蛋白啟動子( polyhedrin promoter)及 pl0 啟動子(pl0 proinoter),此201006928 IX. Description of the invention: « [Technical field to which the invention belongs] % The present invention relates to the surface of a foreign gene (4). A general-purpose baculovirus surface presentation system. [Prior Art] In addition to being a bio-pesticide with great potential in organic agriculture, baculovirus is an important source of exogenous egg whites in industrial and medical fields today. The baculovirus is only good for money, and there are about _ species. The invertebrates on 2 are baculovirus hosts, most of which are insects, including Lepidoptera, Hymenoptera, Diptera and Coleoptera, and Lepidoptera Kun A is the main host of baculovirus. The scorpion virus can be subdivided into two subfamilies. The true subfamily (Eubacui 〇virjnae) and the naked genus (Nudibaculovirinae), the true baculovirus subfamily has a fine knife for two The genus granulosis virus (grimw/o illusion y; GV) has a strong polyhedrin promoter (Q nuclear polyhedrosis virus., ΝΡλ/) ·, the nucleoside polyhedrosis virus contains a strong polyhedrin promoter ( Polyhedrin promoter) and pl0 promoter (pl0 proinoter), this
二種啟動子皆為核多角體病毒非必要結構之基因,該二種 啟動子之損壞並不會影響核多角體病毒在昆蟲細胞的複製 ' 與增殖,因此該核多角體病毒之多角體蛋白啟動子及plO 啟動子常被利用於啟動外源基因的表現,使插入核多角體 病毒基因中之外源基因可在多角體蛋白啟動子及pl〇啟 動子的轉錄調控下獲得極佳的表現量。 目前以苜蓿尺礎蛾核多角禮病毒 201006928 calif or nica multiple nucleocapsid polyhedrosis viruses; AcMNPV)為最常被應用於表現外源基因之桿狀病毒;另 外,常用於被桿狀病毒感染的宿主細胞為秋行軍蟲 (Spodoptera frugiperda ; Sf)的蛹期卵巢組織(pUpai ovariantissue)細胞,通常稱為Sf細胞;Sf細胞可分為 Sf-9及Sf-21二種細胞株’該二種細胞株對苜蓿尺蠖蛾核 多角體病毒皆具有高度的感受性,且Sf-9及Sf-21二種 細胞株皆可被大量懸浮培養,而生產出的重組蛋白質經由 適當的轉譯後可被修飾(post-translational modification); 因此苜蓿尺蠖蛾核多角體病毒搭配Sf細胞株的組合係現 今應用最為廣泛的昆蟲桿狀病毒基因表現系統。 桿狀病毒表面呈現系統係透過gp64基因來運作。 gp64是桿狀病毒套膜表面之主要醣蛋白,將外源蛋白基 因與gp64醣蛋白基因進行基因重組後,可將外源蛋白呈 現在桿狀病毒套膜表面。gp64蛋白質主要由n端訊號序 列和主要區域所構成,此主要區域又分為穿膜區域 (transmembrane domain; TM)及細胞質區域(cytoplasmic domain ; CTD) 〇 gp64蛋白在表現之後會經由訊號序列作 用運送到細胞膜。主要區域則以三聚體結構呈現在受感染 之細胞表面。直到新合成之核殼體要出芽時,再與gp64 之胞質區域交互作用’導致gp64和核殼體結合而展現在 病毒套膜上。 一般傳統的桿狀病毒表現系統係利用桿狀病毒之共 轉染反應騎重師狀病baculovirus)之 6 — 201006928 建構’共轉染反應係利用 經過基因重組的轉殖載體與本身具有之缺陷基因 進行同源互換,以產生帶古f:有缺陷的桿狀病毒基因 在此過程令亦會產生未發同疋基因的重組桿狀病毒;但 須再進一步 二換::狀病毒,因此必 驗法㈣2 而病毒斑純化及免疫分析等實Both promoters are genes of a nuclear polyhedrosis virus non-essential structure, and the damage of the two promoters does not affect the replication and proliferation of nuclear polyhedrosis virus in insect cells, so the polyhedrosis protein of the nuclear polyhedrosis virus The promoter and plO promoter are often used to initiate the expression of foreign genes, so that the foreign gene inserted into the nuclear polyhedrosis virus gene can achieve excellent performance under the transcriptional regulation of the polyhedrin promoter and the pl〇 promoter. the amount. Currently, it is the most commonly used baculovirus for the expression of foreign genes; in addition, it is commonly used in baculovirus-infected host cells for autumn. 201006928 calif or nica multiple nucleocapsid polyhedrosis viruses; AcMNPV) Spdai ovariantissue cells of Spodoptera frugiperda (Sf), commonly referred to as Sf cells; Sf cells can be divided into two cell lines, Sf-9 and Sf-21. The moth-core polyhedrosis virus is highly sensitive, and both Sf-9 and Sf-21 cell lines can be cultured in large quantities, and the recombinant protein produced can be post-translationally modified by appropriate translation. Therefore, the combination of the scorpion scorpion nucleopolyhedrovirus and the Sf cell line is the most widely used insect baculovirus gene expression system. The baculovirus surface rendering system operates through the gp64 gene. Gp64 is the major glycoprotein on the surface of the baculovirus envelope. After the foreign protein gene is genetically recombined with the gp64 glycoprotein gene, the foreign protein can be presented on the surface of the baculovirus envelope. The gp64 protein is mainly composed of an n-terminal signal sequence and a main region, and the main region is further divided into a transmembrane domain (TM) and a cytoplasmic domain (CTD). The gp64 protein is transported by a signal sequence after performance. Go to the cell membrane. The main region is presented on the surface of infected cells in a trimer structure. Until the newly synthesized nucleocapsid is to bud, it interacts with the cytoplasmic region of gp64, causing gp64 to bind to the nucleocapsid and appear on the viral envelope. The conventional baculovirus expression system utilizes the co-transfection reaction of baculovirus to ride the baculovirus of the baculovirus. 6 - 201006928 Construction of the 'co-transfection reaction system utilizes the genetically modified transfer vector and its own defective gene Perform homologous interchange to generate a recombinant baculovirus with an ancient f: defective baculovirus gene in this process, which will also produce a homologous gene; however, it must be further replaced by a virus: Method (4) 2 and virion purification and immunoassay
之建構少一個月的時間,導致傳統重組桿狀病毒 之建構方式具有耗費時間之缺點。 為了迅速的製作重轉狀病毒,出現了—種已知的 旱狀病毒表面呈現系統,如中華名國專利申請第 主 號之刺激誘發對禽流感免疫體原性之假型桿狀 病毋"係利用Bac-to-Bac®系統(Invitrogen公司製造) 來氣作重組桿狀病毒載體,Bae_tQ_Bae⑧系統包含一株同 時帶有柃狀病毒穿梭載體(bacmid)及輔助載體(helper plasmid)的勝任細胞Dm〇Bac,該DH1〇Bac係為一大腸 才干菌株’輔助載體帶有可以表現轉置酶(transp〇sase)的基 因,將帶有外源基因、Tn7R及Tn7L基因跳躍點的表現 載體利用轉型(transformati〇n)的方法送入勝任細胞 DHlOBac’該桿狀病毒穿梭載體亦具有Tn7R及Tn7L 基因跳躍點,透過輔助載體上面所轉譯的轉置酶使桿狀病 毒穿梭載體與該表現載體之基因跳躍點間的基因產生互換 ’使欲表現的外源基因跳入桿狀病毒穿梭載體内,此基因 跳躍互換之過程稱之為轉置作用,而桿狀病毒穿梭載體内 的Tn7R及Tn7L基因跳躍點間有lacZ基因,當基因跳 201006928 躍發生時會將該lacZ基因打斷,使得轉型成功以及完成 ♦ 基因跳躍之DHlOBac菌落在含有χ-gal及IPTG的培養 * 基上呈現白色;挑選該呈現白色之DHlOBac菌落直接進 行穿梭載體之純化,不需要進行病毒斑之純化,而大幅減 少製作重組桿狀病毒之時間。 該已知桿狀病毒表面呈現系統係利用所構築之重組 載體Bac-HA及Bac-HA64表現禽流感病毒之紅血球凝集 蛋白’以製備H5N1禽流感疫苗;其中該Bac_HA載體係 於一 pBacCE質體中依序插入gp64訊號序列(gp64 signal sequence ; gp64 SS)、6 個組胺酸殘基(His6 tag)、禽流 感病毒之紅血球凝集素基因穿膜區(HA穿膜區;ΉΑThe construction takes less than a month, which leads to the shortcomings of the traditional restructuring of the baculovirus construction. In order to rapidly produce re-transformed viruses, a known surface-presenting system for dry-type viruses has emerged, such as the stimuli of the Chinese patent application for the induction of avian flu-like symptoms of avian influenza. The Bac-to-Bac® system (manufactured by Invitrogen) is used as a recombinant baculovirus vector, and the Bae_tQ_Bae8 system contains a competent cell carrying a coronavirus shuttle vector (bacmid) and a helper plasmid. Dm〇Bac, the DH1〇Bac is a large intestine strain's helper vector with a gene that can express transp〇sase, and transforms the expression vector with exogenous gene, Tn7R and Tn7L gene jumping points. The method of (transformati〇n) is sent to the competent cell DHlOBac'. The baculovirus shuttle vector also has a Tn7R and Tn7L gene jumping point, and the baculovirus shuttle vector and the gene of the expression vector are translocated by the transposase translated on the helper vector. The gene exchange between the jumping points is such that the foreign gene to be expressed jumps into the baculovirus shuttle vector, and the process of this gene jump exchange is called transposition. There is a lacZ gene between the Tn7R and Tn7L gene hopping points in the baculovirus shuttle vector. When the gene jumps 201006928, the lacZ gene is interrupted, which makes the transformation successful and completes the DX gene hopping DHlOBac colony containing χ-gal and The culture of IPTG* was white on the basis; the DHlOBac colony which was white was selected to directly purify the shuttle vector, and the purification of the plaque was not required, and the time for preparing the recombinant baculovirus was greatly reduced. The known baculovirus surface presentation system utilizes the constructed recombinant vectors Bac-HA and Bac-HA64 to express the avian influenza virus erythrocyte agglutinin ' to prepare an H5N1 avian influenza vaccine; wherein the Bac_HA vector is in a pBacCE plastid Insert gp64 signal sequence (gp64 SS), 6 histidine residues (His6 tag), avian influenza virus erythrocyte lectin gene transmembrane region (HA transmembrane region;
transmembrane domain ; HA ΤΜ)及禽流感病毒之紅血球 滅集素基因之細胞質區(HA cytoplasmic domain ; HA CTD)或;f干狀病毒細胞質區(gp^ Cyt〇plasmic domain; gp64 CTD )。 ◎由於該已知桿狀病毒表面呈現系統之穿膜區係選用 禽流感病毒之紅血球凝集素基因穿膜區,而未使用桿狀病 毒穿膜區,使得禽流感病毒之紅血球凝集蛋白的表現量不 - 佳’導致該已知桿狀病毒表面呈現系、统具有外源蛋白 #效率*佳之缺點;另外H减病毒之紅血球凝集素 基因外部區並無設計任何限制酶切位,而無法進行該禽流 感病毒紅血球凝集素基因之剔除或連接,而限制該已知的 桿狀病毒表面呈現系統僅能被使用於表現禽流感病毒之紅 血球凝集蛋白且僅可被使用一次,使該已知桿狀病毒表面 201006928 且無法被重複使 呈現系統具有僅可表現禽流感病毒蛋白 用於表現不同外源蛋白之缺點。 【發明内容】 本發日狀為改善已知的桿狀病毒表面呈現系統表現 =率不佳、僅能表現單-種外源蛋白及無法被重複使用於 表現外源蛋白之缺點,進行努力研究而研發出—種泛用型 桿狀病毒表面呈現系統(universal baeulQvims surfaeeTransmembrane domain; HA ΤΜ) and avian influenza virus erythrocyte cytoplasmic domain (HA cytoplasmic domain; HA CTD) or; f cytoplasmic cytoplasmic domain (gp^ Cyt〇plasmic domain; gp64 CTD). ◎Because the transmembrane region of the known baculovirus surface presentation system uses the erythrocyte lectin gene transmembrane region of avian influenza virus, and the baculovirus transmembrane region is not used, the avian influenza virus erythrocyte agglutination protein expression amount Not-good' causes the known baculovirus surface to appear, and has the disadvantage of exogenous protein #efficiency*; in addition, the H-reducing erythropoietin gene outer region does not have any restriction enzyme cleavage position, and cannot be performed. Elimination or ligation of the avian influenza virus red blood cell lectin gene, while limiting the known baculovirus surface presentation system can only be used to express avian influenza virus erythrocyte agglutinin and can only be used once, making the known rod The viral surface 201006928 and cannot be repeated allows the rendering system to have the disadvantage of showing only avian influenza virus proteins for the expression of different foreign proteins. SUMMARY OF THE INVENTION The present invention is to improve the known baculovirus surface presentation system performance = poor rate, can only express single-type foreign proteins, and can not be reused to express foreign protein defects, and work hard to study Developed a universal baculovirus surface rendering system (universal baeulQvims surfaee)
如play system ; U則DS),其可以提高外源蛋白在病毒表 面之表現量’且該泛用型桿狀病毒表面呈現系統可被重複 使用於表現多種之外源蛋白,以應用於多種次單位疫苗之 製備。 本發明之主要目的係提供一種泛用型桿狀病毒表面 呈現系統’其係藉由將瓜0 I、I、户对I及五⑺及I四 個高效率限制酶切位選殖入重組載髏之6個組胺酸殘基及 gP64穿膜區之間,以供不同外源基因進行連接或剔除, 使得本發明具有可被重複使用於表現不同外源蛋白之功效 本發明之次一目的係提供一種泛用型桿狀病毒表面 呈現系統,其係選用桿狀病毒本身之gp64穿膜區來表現 外源蛋白,使得本發明具有可提高外源蛋白特異性及外源 蛋白在桿狀病毒表面的表現量之功效。 本發明另一目的’係利用Bac-to-Bac系統以進行簡 易之蛋白純化過程’使得本發明具有可大幅縮短蛋白純化 所需時間之功效。 201006928Such as play system; U is DS), which can increase the amount of foreign protein expression on the surface of the virus' and the general-purpose baculovirus surface presentation system can be reused to express a variety of foreign proteins for multiple applications. Preparation of unit vaccines. The main object of the present invention is to provide a general-purpose baculovirus surface presentation system which selects four high-efficiency restriction enzyme sites of melon, I, I, I and five (7) and I into a recombinant load. The six histidine residues and the gP64 transmembrane region are ligated or eliminated by different foreign genes, so that the present invention has the effect of being reusable for expressing different foreign proteins. The invention provides a general-purpose baculovirus surface presentation system, which uses the gp64 transmembrane region of the baculovirus itself to express the foreign protein, so that the invention has the specificity of exogenous protein and the foreign protein in the baculovirus. The effect of the amount of surface performance. Another object of the present invention is to utilize the Bac-to-Bac system for the simple protein purification process, so that the present invention has the effect of greatly shortening the time required for protein purification. 201006928
本發明係提供-種泛用型桿狀病毒表面呈現系統, 其所構築之重組載體具有桿狀病毒gp64蛋白質的訊息序 列、穿膜區基因、細胞質區基因及六個組胺酸序列,並將 遍I、為I、尸对ϊ及五coiM四個高效率之限制酶切位 選殖入該六個組胺酸序列及gp64穿膜區之間,使該泛用 型桿狀病毒表面呈現系統可將不同的外源蛋白大量表現於 桿狀病毒之套膜上,以應用於不同次單位疫苗之製備。 【實施方式】 為了讓本發明之上述和其他目的、特徵和優點能更 明確被了解’下文將特舉本發明較佳實施例,並配合所附 圖式,作詳細說明如下。 一、泛用型桿狀病毒表面呈現平台pBacSC:之構築The present invention provides a general-purpose baculovirus surface presentation system, which comprises a baculovirus gp64 protein message sequence, a transmembrane region gene, a cytoplasmic region gene and six histidine sequences, and Four high-efficiency restriction sites of I, I, cadaver and five coiM were selected between the six histidine sequences and the gp64 transmembrane region to make the general-purpose baculovirus surface presentation system Different exogenous proteins can be expressed in large quantities on the baculovirus envelope for the preparation of different subunit vaccines. The above and other objects, features, and advantages of the present invention will become more apparent <RTIgt; </ RTI> <RTIgt; </ RTI> <RTIgt; First, the general-purpose baculovirus surface presentation platform pBacSC: the construction
本發明之構築泛用型桿狀病毒表面呈現平台pBacSCThe invention discloses a general-purpose baculovirus surface presentation platform pBacSC
的第一步驟:係取pFastBac Dual載體(Invitrogexi公司製 造),該pFastBac Dual載體帶有Tn7R跳躍基因、Tn7L 跳躍基因、多角體蛋白啟動子及pl〇啟動子。在該 pFastBac Dual載體中之多角體蛋白啟動子下游插入巨細 胞病毒綠色螢光蛋白基因(cytomegalovirus immediate early promoter- enhanced green fluorescent protein ; CMV-EGFP)以構築成pBacCE载體;再於該pBacCE載體plO 啟動子下游插入gp64組胺酸(His-gp64)成熟區基因以 構築成pBacCEH載體。The first step: the pFastBac Dual vector (manufactured by Invitrogexi Co., Ltd.) carrying the Tn7R skip gene, the Tn7L skip gene, the polyhedrin promoter and the pl〇 promoter. A cytomegalovirus immediate early promoter-enhanced green fluorescent protein (CMV-EGFP) is inserted downstream of the polyhedrin promoter in the pFastBac Dual vector to construct a pBacCE vector; and the pBacCE vector plO The gp64 histidine (His-gp64) mature region gene was inserted downstream of the promoter to construct a pBacCEH vector.
本發明之構築泛用型桿狀病毒表面呈現平台pBacSC 的第二步驟:係取該pBacCEH載體做為模板,以引子A 201006928 (序列編號 1 : 5’-ATATCCCGGGATGCTACTAGTAAATC AGTCACAC-3,)及帶有 6 個組胺酸(histidine, GTG)之 引子 B (序列編號 2 : 5’-TAGC CTCGAGGTG GTG GJG GTG GTG GTGCGC -3’)進行聚合酶連鎖反應以擴增出 gp64 訊息序列(gp64 signal sequence ; gp64 SS)及組胺酸標 籤(His tag),其擴增後產物預期大小應為147 bp。另外 亦以pBacCEH為模板,以引子F (序列編號3 : 5’-ATATGGTACCTTAATATTGTCTATTACGGTTTC -3,)及 帶有I ( CTCGAG) ^ Xba 1 ( TCTAGA) - Pst I ( CTGCAG)及EcoR 1 (GAATTC)四個限制酶切割位序 列之引子CTD (序列編號4 : 5’- GGTCTCGAG TCTAGA CTGCAG GAMTCTTCATGTTTGGTCATGTAGTTA -3^) 進行聚合酶連鎖反應擴增出gp64穿膜區(gp64 transmembrane domain ; gp64 TM)及 gp64 細胞質區(gp64 cytoplasmic domain ; gp64 CTD),擴增後產物大小應為 123 bp ’利用聚合酶連鎖反應將瓜ο z卜户对i及 五⑺及I四個高效率限制酶切位選殖入重組載體,使得該重 組載體可被重複使用於表現多種外源蛋白之功效;且選用 桿狀病毒本身之gp64穿膜區來表現外源蛋白,使得該重 組載體可提高外源蛋白特異性及表現量(Yang et al, 2〇〇7) ’再分別將此二次聚合酶連鎖反應之產物進行瓊脂膠電泳 分析,以確定選殖入重組載體之基因片段正確無誤。 如第1圖所示,利用限制酶切割與連接作用將該 gp64訊息序列_組胺酸標誌(大小為147 bp)基因片段及 —11 — 201006928 gp64穿膜區哪64細胞質區(大小為123 bp)基因片段 到帶有巨細胞病毒綠色榮光白基因的載禮邮咖上,^ • $成泛用型桿狀病毒表面呈現平台之構築,並將此平台二 名為pBacSC’而利用該平台pBacSC表現外源蛋白的系 統稱之為泛用型桿狀病毒表面呈現系統(imiversal baculovirus surface display system ; UBSDS)。 該泛用型桿狀病毒表面呈現平台pBacSC係選用桿狀 病毒本身之卽64穿膜區之設計,可提高外源蛋白在病毒 封套上的穩定性與表現量。另外,在該泛用型桿狀病毒表 面呈現平台pBacSC於該六個組胺酸序列及gp64穿臈區 之間選殖入JOw II、户对I及五⑶及I四個高效率限 制酶切位之設計,使該泛用型桿狀病毒表面呈現平台 pBacSC可供不同的外源基因構築至pBacS(:平台,且亦 可將該外源基因利用限制酶切割進行剔除後,再進行另一 種外源基因之構築;進而使該pBacSC平台可重複進行不 g 同的外源基因之構築。在完成該pBacSC平台之構築後, 進一步鑑定該pBacSC平台之正確性。 二、泛用型桿狀病毒表面呈現平台pBacSC之鑑定 • 本發明之鑑定該泛用型桿狀病毒表面呈現平台 pBacSC係取該泛用型桿狀病毒呈現平台pBacSC做為模 板,以A/B引子組與F/CTD引子組針對該pBacSC平台 進行聚合酶連鎖反應,以確定該gp64訊息序列-組胺酸標 籤基因片段及gp64跨膜區-gp64細胞質區基因片段是否 已成功構築至pBacCE載體上;結果如第2圖所示,其中 —12 — 201006928The second step of constructing the universal baculovirus surface presenting platform pBacSC of the present invention: taking the pBacCEH vector as a template, using primer A 201006928 (sequence number 1: 5'-ATATCCCGGGATGCTACTAGTAAATC AGTCACAC-3), and with 6 A histidine (GTG) primer B (SEQ ID NO: 2: 5'-TAGC CTCGAGGTG GTG GJG GTG GTG GTGCGC -3') undergoes a polymerase chain reaction to amplify the gp64 signal sequence (gp64 signal sequence; gp64 SS) And histidine tag (His tag), the expected size of the amplified product should be 147 bp. In addition, pBacCEH is used as a template, with primer F (sequence number 3: 5'-ATATGGTACCTTAATATTGTCTATTACGGTTTC -3,) and with I (CTCGAG) ^ Xba 1 ( TCTAGA) - Pst I ( CTGCAG) and EcoR 1 (GAATTC) The primer for the restriction enzyme cleavage sequence CTD (SEQ ID NO: 4: 5'- GGTCTCGAG TCTAGA CTGCAG GAMTCTTCATGTTTGGTCATGTAGTTA -3^) polymerase chain reaction to amplify the gp64 transmembrane domain (gp64 TM) and gp64 cytoplasmic region (gp64) Cytoplasmic domain; gp64 CTD), the size of the amplified product should be 123 bp. 'The polymerase chain reaction is used to select the four high-efficiency restriction sites of me and z (7) and I into the recombinant vector. The recombinant vector can be repeatedly used to express the efficacy of various foreign proteins; and the gp64 transmembrane region of the baculovirus itself is used to express the foreign protein, so that the recombinant vector can increase the specificity and expression of the foreign protein (Yang et et Al, 2〇〇7) 'The products of the secondary polymerase chain reaction were separately subjected to agarose gel electrophoresis analysis to confirm that the gene fragment cloned into the recombinant vector was correct. As shown in Figure 1, the gp64 message sequence _ histidine marker (size 147 bp) gene fragment and the -11 cytoplasmic region (123 bp in size) were blocked by restriction enzyme cleavage and ligation. Gene fragment into a gift-bearing coffee-tea with a cytomegalovirus green glory white gene, ^• into a generic baculovirus surface rendering platform, and the platform two named pBacSC' and use the platform pBacSC The system for expressing foreign proteins is called the imiversal baculovirus surface display system (UBSDS). The general-purpose baculovirus surface presentation platform pBacSC uses the design of the 穿64 transmembrane region of the baculovirus itself to improve the stability and performance of the foreign protein on the viral envelope. In addition, on the surface of the general-purpose baculovirus, the platform pBacSC was selected between the six histidine sequences and the gp64 translocation region, and the four high-efficiency restriction enzymes were selected for JOw II, household to I, and five (3) and I. The design of the universal baculovirus surface presentation platform pBacSC allows different foreign genes to be constructed into pBacS (: platform, and the exogenous gene can also be removed by restriction enzyme cleavage, and then another The construction of the foreign gene; and further, the pBacSC platform can repeat the construction of the foreign gene which is not identical. After the construction of the pBacSC platform is completed, the correctness of the pBacSC platform is further identified. 2. Universal baculovirus Identification of the surface presentation platform pBacSC • Identification of the universal baculovirus surface presentation platform pBacSC takes the generic baculovirus presentation platform pBacSC as a template, with A/B introduction group and F/CTD introduction group A polymerase chain reaction was performed on the pBacSC platform to determine whether the gp64 message sequence-histidine tag gene fragment and the gp64 transmembrane region-gp64 cytoplasmic region gene fragment have been successfully constructed into a pBacCE vector; As shown in Figure 2, where -12 — 201006928
Lane Μ為標準條帶;Lane 1為以A/B引子組針對該 阳獅平台所擴增之產物,其大小為147 bp ; Lane 2為 F/CTD引子組針對該pBacSC平台所擴增出之產物,其大 J為123 bp,由此結果可確定該卽64訊息序列組胺酸標 籤基因片段及gP64跨膜區_gp64細胞質區基因片段已成 功構築至pBacCE载體上,即可確定已成功構築泛用型桿 狀病毒表面呈現平台pBacsc。 在確定成功構築該pBacSC平台後,進一步利用該 pBacSC平台表現不同的外源蛋白,本發明人係利用該 pBacSC平台表現家禽里奥病毒蛋白及豬瘟病毒蛋白。 三、利用pBacSC平台表現不同外源蛋白利用pBacSC:表 現家禽里奥病毒之cjC及σΒ蛋白 家禽里奥病毒之orC及σΒ蛋白具有誘導產生群專一 性及中和抗體的功能。本發明之利用pBacSC表現家禽里 奥病毒aC及σΒ蛋白的第一步驟:係根據家禽里奥病毒 基因序列設計σ C-F引子(序列編號5 : 5’-ATAGGTCGACTTAATGGCGGGTCTCAATCCATCGCAGC •3,)/aC-R 引子(序列編號 6 : 5,-GCGCGAATTCTTCGG TGTCGATGCCGGTACGCACGG-3’)引子組及 σ B-F (序 列編號 7 : 5’- GCGCTCGAGTTAATG GAGGTACGTGTGC CAAAC -3,)ΑτΒ-R (序列編號 8 : 5,- CCGGGAATTCTTC CCAACCACACTCCACTTCAGTG -3,)引子組,且以該 aC-F/aC-R引子組及該σΒ-FMB-R引子組針對家禽里奥 —13 — 201006928 ::基仃聚合酶連鎖反應,以擴增家禽里奥病毒之。 σ(:及j本翻之彻pBaeSC表現家禽里奥病毒 σ自㈣二步驟:雜該制之家禽里奥病毒 °^σΒ基因以限制内切酶歸行酵素 =同時將pBacSC栽鳢以万^心和為…切酶進行 主’、刀」如第3圖所示,將pBacSC載體與家禽里奥病 及⑽基因進行接合作用(ligation),以構筚重 組桿狀病毒麵及一❿池。構築重Lane Μ is a standard band; Lane 1 is a product amplified by the A/B primer group for the lion platform, and its size is 147 bp; Lane 2 is the F/CTD primer group amplified for the pBacSC platform. The product, the large J is 123 bp, and the result can be confirmed that the 卽64 message sequence histidine tag gene fragment and the gP64 transmembrane region _gp64 cytoplasmic region gene fragment have been successfully constructed on the pBacCE vector, and the determination has been successful. Construct a pan-like baculovirus surface presentation platform pBacsc. After determining that the pBacSC platform was successfully constructed, the pBacSC platform was further utilized to express different foreign proteins, and the inventors used the pBacSC platform to express the poultry virus virus and the swine fever virus protein. Third, the use of pBacSC platform to express different foreign proteins using pBacSC: the cjC and σΒ protein of poultry virus. The orC and σΒ proteins of poultry virus have the function of inducing group specificity and neutralizing antibodies. The first step of the present invention for expressing poultry virus AC and σΒ protein using pBacSC is: designing a σ CF primer according to the sequence of the poultry virus gene (SEQ ID NO: 5: 5'-ATAGGTCGACTTAATGGCGGGTCTCAATCCATCGCAGC • 3,) / aC-R primer ( SEQ ID NO:6: 5,-GCGCGAATTCTTCGG TGTCGATGCCGGTACGCACGG-3') Introduction group and σ BF (SEQ ID NO: 7: 5'-GCGCTCGAGTTAATG GAGGTACGTGTGC CAAAC -3,) ΑτΒ-R (SEQ ID NO: 8: 5, - CCGGGAATTCTTC CCAACCACACTCCACTTCAGTG -3,) The primer group, and the aC-F/aC-R primer group and the σΒ-FMB-R primer group were used to amplify the poultry virus of the poultry Leo-13-201006928:-based polymerase chain reaction. σ (: and j 翻 翻 翻 pBaeSC performance poultry rio virus σ from (four) two steps: miscellaneous system of poultry virus virus ° ^ σ Β gene to limit endonuclease enzymes = at the same time pBacSC planted 10,000 ^ The heart and the cleavage enzyme are the main 'knife'. As shown in Fig. 3, the pBacSC vector is ligated with the poultry rio disease and the (10) gene to construct a recombinant baculovirus surface and a pool. Construct weight
本發明之利用pBacSc表現家禽里奥病毒Μ及心 白的第二步驟.係彻B^t(KBae系統將該構築好之 ^ s σ(:载體及pBaeS(^B載體上之特定基因片段藉 轉置作用互換置人勝任細胞之穿梭載體上,將該經過轉 置作用之勝任細胞培養二至三天,挑選出轉置成功之白色 菌落,並進行聚合酶連鎖反應擴增aC及σΒ基因片段予 以禮認’且大量培養軸雜置之,再歸該菌株之 重組穿梭载體DNA ;將細胞轉染試劑(eellfeetin reagent )與重組?梭紐職於室溫下混合3G分鐘,取該混 合液加入含有Sf_9細胞株之細胞培養盤(weU)中,於 27 C培養5小時後抽出混合液,並於該混合液加入含有 ίο%胎牛企清及三合一抗生素& 培養液,再置 於27 C培養箱培養3天,進行離心、取上清液,該上清 液即含有BacSC-cjC及BacSC-σΒ重組桿狀病毒顆粒。 該BacSC-aC重組桿狀病毒可表現帶有gp64訊號區 域、aC結構蛋白、gp64穿膜區及卻64胞質區域的重組 201006928 蛋白;而該BacSC-σΒ重組桿狀病毒可表現帶有gp64訊 號區域、σΒ結構蛋白、gp64穿膜區及gp64胞質區域的 重組蛋白’且該BacSC-aC及BacSC-σΒ重組桿狀病毒皆 帶有組胺酸標誌》再以該BacSC-aC及BacSC-σΒ重組桿 狀病毒感染Sf-9細胞株,並於感染三天後以pH5 5之細 胞培養液(TNM-FH)刺激該受BacSC-aC及BacSC-σΒ 重組桿狀病毒所感染之Sf-9細胞株,於顯微鏡下觀察是 否產生細胞融合現象,並於螢光顯微鏡下觀察是否出現綠 色螢光。 ' 如第4A1、4A2及4A3圖所示,該第4A1圖為未受 BacSC-aC及BacSC-σΒ重組桿狀病毒所感染之Sf_9細胞 株,以做為對照組,該第4A2圖及第4A3圖分別為受 BacSC-σΒ及BacSC-aC重組桿狀病毒感染之Sf_9細胞株 ’於該第4A2圖及第4A3圖中皆可觀察到細胞融合的現 象;而第4B1、4B2及4B3圖係分別以螢光顯微鏡觀察該 對照組、受BacSC-σΒ感染之Sf-9細胞株及受BacSC-aC 感染之Sf-9細胞株的結果,該對照組無產生任何螢光現 象’而受BacSC-σΒ感染之Sf-9細胞株及受BacSC-aC感 染之Sf-9細胞株皆出現綠色螢光;藉由產生細胞融合及 綠色螢光’即可確定該BacSC-σΒ及BacSC-oC重組桿狀 病毒已成功感染Sf-9細胞株。 在確定該BacSC-σΒ及BacSC-oC重組桿狀病毒已成 功感染Sf-9細胞株後’本發明之利用pBacSC表現家禽里 奥病毒σ(:及σΒ蛋白的第四步驟:係進一步確認重組桿 —15—— 201006928 狀病毒BacSC-σC、BacSC-σΒ可表現家禽里奥病毒。 及σΒ蛋白。將構築好的重組桿狀病毒BacS(:_ σ〇 BacSC-σΒ及未帶有aC及σΒ蛋白基因的對照級 BacSC感染Sf-9昆蟲細胞,感染三天後,再進^西口 點法(Western blot)分析,結果請參照第5A圖及第 圖’其Lane 1皆為標準條帶(Marker),Lane 2分別為被 BacSC-σΒ與BacSC-aC感染之Sf_9昆蟲細胞^ 3 Ο Ο 皆為被BacSC感染之Sf-9昆蟲細胞,Lane 4皆為未為任 何感染之Sf-9昆蟲細胞,結果顯示以BacSC感毕的之sf 9昆蟲細胞及Sf-9昆蟲細胞,皆未出現任何蛋白可以被浐 crC及抗σΒ的一級抗體(jC D11單株抗體或抗雞多= 抗體)所辨識;而以BacSC-σΒ及BacSC-aC感染的Sf_ 9昆蟲細胞,在38及36 KD的大小位置出現被一級抗體 辨識之反應;由該西方墨點法分析之結果可確曹纟二 病毒BacSC-crC、BacSC-σΒ可表現家禽里奥病毒及 ο* B蛋白。 本發明之利用pBacSC表現家禽里奥病毒σ(: 蛋白的第五步驟:係進一步確認泛用型桿狀病毒表面呈現 系統(UBSDS)可將重組蛋白cjC及crB呈現在病毒套膜上 。取 M0I 10 病毒劑量的 BacSC- σ C、Bacsc_ cr β 及The second step of the present invention using pBacSc to express the poultry virus virus and the white heart of the poultry is the B^t (the KBae system constructs the ^s σ (the vector and the pBaeS (the specific gene fragment on the ^B vector) The transplanted carrier is exchanged on the shuttle vector of the competent cells by transposition, and the transposed cells are cultured for two to three days, and the transfected white colonies are selected, and the polymerase chain reaction is used to amplify the aC and σΒ genes. The fragment is ritually recognized and a large number of culture shafts are mixed, and then the recombinant shuttle vector DNA of the strain is added; the cell transfection reagent (eellfeetin reagent) is mixed with the recombinant sulphonate at room temperature for 3G minutes, and the mixture is taken. The solution was added to a cell culture plate (weU) containing the Sf_9 cell strain, and after 5 hours of incubation at 27 C, the mixture was withdrawn, and the mixture was added to the mixture containing ίο% fetal calf and three-in-one antibiotic & culture solution, and then placed. The 27 C incubator was cultured for 3 days, centrifuged, and the supernatant was taken. The supernatant contained BacSC-cjC and BacSC-σΒ recombinant baculovirus particles. The BacSC-aC recombinant baculovirus can express the region with gp64 signal. , aC structural protein, gp64 wear Recombinant 201006928 protein in the membrane region and in the 64 cytoplasmic region; and the BacSC-σΒ recombinant baculovirus can express a recombinant protein with a gp64 signal region, a σΒ structural protein, a gp64 transmembrane region, and a gp64 cytoplasmic region and the BacSC -aC and BacSC-σΒ recombinant baculovirus all carry a histidine marker and then infect the Sf-9 cell line with the BacSC-aC and BacSC-σΒ recombinant baculovirus, and the cells with pH 5 5 after three days of infection The culture medium (TNM-FH) stimulated the Sf-9 cell line infected with BacSC-aC and BacSC-σΒ recombinant baculovirus, observed whether cell fusion occurred under a microscope, and observed whether green was observed under a fluorescence microscope. Fluorescence. ' As shown in Figures 4A1, 4A2 and 4A3, Figure 4A1 shows Sf_9 cell line not infected with BacSC-aC and BacSC-σΒ recombinant baculovirus as a control group, Figure 4A2 And Figure 4A3 shows that the Sf_9 cell line infected with BacSC-σΒ and BacSC-aC recombinant baculovirus respectively can observe the phenomenon of cell fusion in the 4A2 and 4A3 images; and 4B1, 4B2 and 4B3 The control group was observed by fluorescence microscope, and was infected with BacSC-σΒ. As a result of the Sf-9 cell line and the Sf-9 cell line infected with BacSC-aC, the control group did not produce any fluorescence phenomenon, and the Sf-9 cell line infected with BacSC-σΒ was infected with BacSC-aC. The Sf-9 cell line showed green fluorescence; the cell fusion and green fluorescence were used to confirm that the BacSC-σΒ and BacSC-oC recombinant baculovirus had successfully infected the Sf-9 cell line. After determining that the BacSC-σΒ and BacSC-oC recombinant baculovirus have successfully infected the Sf-9 cell line, the fourth step of the present invention using the pBacSC to express the poultry virus σ(: and σΒ protein: further confirming the recombination rod —15 — 201006928 The prion BacSC-σC and BacSC-σΒ can express the poultry virus and σΒ protein. The recombinant baculovirus BacS (:_ σ 〇BacSC-σΒ and without aC and σΒ protein will be constructed. The control level BacSC of the gene infects Sf-9 insect cells, and after three days of infection, it is further analyzed by Western blot analysis. For the results, please refer to Figure 5A and Figure 'The Lane 1 is the standard strip (Marker). Lane 2 is Sf_9 insect cells infected by BacSC-σΒ and BacSC-aC respectively. 3 Ο Ο are Sf-9 insect cells infected with BacSC, and Lane 4 is not infected with any Sf-9 insect cells. No sf 9 insect cells and Sf-9 insect cells showing BacSC sensation were found to be recognized by 浐crC and anti-σΒ primary antibody (jC D11 monoclonal antibody or anti-chicken = antibody); Sf-9 insect cells infected with BacSC-σΒ and BacSC-aC at 38 and 3 The size of 6 KD appears to be recognized by the primary antibody; the results of the Western blot analysis can confirm that the Cao 纟 virus BacSC-crC, BacSC-σΒ can express the poultry rio virus and the ο* B protein. The pBacSC is used to express the poultry virus σ (the fifth step of the protein: further confirming the general-purpose baculovirus surface presentation system (UBSDS) to present the recombinant proteins cjC and crB on the viral envelope. Take the M0I 10 virus dose BacSC- σ C, Bacsc_ cr β and
Bac-SC,感染Sf-9昆蟲細胞,於適當的條件下對該受感 染之Sf-9昆蟲細胞培養兩天後,與抗σ(:及抗cjb的一級 抗體進行作用’再以免疫螢光(flU〇rescein isQthiQeyanate ;FITC)標記及共輛焦顯微鏡的方法觀察,以確認表現 201006928 • #重組0^ &σΒ蛋白表現在昆蟲細胞JL的位置。如第6 ’該帛6 ®仙錄焦臟贱躲贿識結果之 • 觀察’該結果顯示以重組病毒BacSC (對照組)所感染的 Sf9昆蟲細胞’無出現任何蛋白可被一級抗體所辨識;而 以重組病毒BacSC_JC及BacSC-σΒ感染後’可觀察到 細胞膜表面有重、址蛋白的呈現,此結果再證明了所表現的 重組蛋白iJC及σΒ可表現在sf_9昆蟲細胞的表面。進一 ❹ ?將重組桿狀病毒BaeSC_cjC、BaeSC-σΒ及Bac-SC以 庶糖濃度梯度超高速離心的方式將病毒純化,經由免疫金 電子顯微鏡的方法,觀察重組蛋白是否有表現在病毒套膜 上’以確認表現的重組蛋白可有效地呈現在桿狀病毒套膜 上;如第7圖所示,以免疫金電子顯微鏡進行抗體辨識結 果之觀察’該結果顯示BacSC (對照組)並沒有任何金顆 粒在病毒表面上,而ΒΝ8(:_σ(:及BacSC 〇_B確實有金 顆粒出現在桿狀病毒表面上。依據以上之結果可證實透 〇 過泛用型桿狀病毒表面呈現系統(UBSDS)的確可以將重組 蛋白aC及σΒ呈現在病毒套膜上。 家禽里奥病毒(7C及σΒ蛋白應用於次單位疫苗之實驗動 物免疫試狳 . 本發明之家禽里奥病毒JC及(jB蛋白應用於次單位 疫苗的實驗動物免疫試驗,其係選用六至八週齡無特定病 原之實驗動物進行該家禽里奥病毒σ(: &σΒ蛋白之免疫 試驗,其中該實驗動物係小鼠,該實驗小鼠之品系為 BALB/c。以BacSC-aC及BacSC-σΒ為實驗組;並以 —17 一 201006928Bac-SC, infected with Sf-9 insect cells, cultured against infected Sf-9 insect cells under appropriate conditions for two days, and then reacted with anti-sigma (: and anti-cjb primary antibody) and then immunofluorescence (flU〇rescein isQthiQeyanate;FITC) labeling and method observation of a common focal microscope to confirm the performance 201006928 • #recombination 0^ &σΒ protein expressed in the position of insect cell JL. For example, the 6th '帛6 ®仙焦焦Visceral plagiarism • Observations 'The results showed that Sf9 insect cells infected with the recombinant virus BacSC (control group) showed no protein recognized by the primary antibody; whereas after infection with the recombinant viruses BacSC_JC and BacSC-σΒ 'The appearance of heavy and protein on the surface of the cell membrane was observed. This result proves that the expressed recombinant proteins iJC and σΒ can be expressed on the surface of sf_9 insect cells. Further, the recombinant baculovirus BaeSC_cjC, BaeSC-σΒ and Bac-SC purifies the virus by ultra-high speed centrifugation with a concentration of sucrose, and observes whether the recombinant protein is expressed on the viral envelope by immunogold electron microscopy. The recombinant protein can be effectively presented on the baculovirus envelope; as shown in Figure 7, the results of antibody identification by immunogold electron microscopy showed that BacSC (control group) did not have any gold particles on the virus surface. And ΒΝ8(:_σ(: and BacSC 〇_B does have gold particles on the surface of the baculovirus. Based on the above results, it can be confirmed that the ubiquitous baculovirus surface rendering system (UBSDS) can indeed reorganize The protein aC and σΒ are present on the viral envelope. The poultry virus (7C and σΒ protein are used in the experimental animal immunization test of the subunit vaccine. The poultry virus JC of the invention and the jB protein are applied to the subunit vaccine. An experimental animal immunoassay is carried out by using an experimental animal having no specific pathogen of six to eight weeks of age to perform an immunoassay of the poultry virus σ (: & σ Β protein, wherein the experimental animal is a mouse, the strain of the experimental mouse For BALB/c. Take BacSC-aC and BacSC-σΒ as experimental groups; and take -17 to 201006928
BacSC為陰性控制組;將實驗組及陰性控制組織重組病毒 分別感染Sf-9細胞,由於感染重组病毒後的sf-9細胞, 帶有重組病毒蛋白在其細胞膜上;為了研究此細胞對小鼠 是否能有效的誘發免疫反應’因此將感染重組桿狀病毒後 的細胞對小鼠進行免疫試驗,並以酵素結合免疫吸附試驗 (ELISA)測試血清抗體力價。結果如第8圖所示,該 ELISA reader判讀ODmo之結果顯示以被BacSC感染的BacSC was a negative control group; the experimental group and the negative control tissue recombinant virus were respectively infected with Sf-9 cells, and the sf-9 cells infected with the recombinant virus were carried with the recombinant virus protein on the cell membrane; Whether it can effectively induce an immune response' Therefore, the cells infected with the recombinant baculovirus are subjected to an immunoassay, and the serum antibody titer is tested by an enzyme-binding immunosorbent assay (ELISA). The results are shown in Figure 8, and the results of the ELISA reader reading ODmo showed infection with BacSC.
Sf-9細胞及Sf-9細胞注射實驗小鼠後所產生之血清,其 ELISA值均小於〇·4 ;而以被BacSC- σ C感染的Sf-9細胞 ,及被BacSC-σΒ感染的Sf-9細胞注射實驗小鼠所產生 之血清的OD65〇值均高達1.〇以上。由此結果可知此帶有 重組病毒蛋白及σΒ的Sf-9細胞,確實可以引起小鼠 體内免疫反應的產生。 另外,以ARV疫苗(市售家禽里奥S1133株活毒疫 苗)為對照組,以重組病毒BacSCjC、BacSC—jB及 BacSC-(jC+aB (即同時注射重組病毒Baesc-jc與 BacSC-σΒ)為實驗組,並以BacSC及磷酸Sf-9 cells and Sf-9 cells were injected with experimental mice, and the ELISA values were less than 〇·4; and Sf-9 cells infected with BacSC- σ C and Sf infected with BacSC-σΒ The OD65 血清 value of the serum produced by the -9 cell injection test mice was as high as 1.〇 or more. From this result, it was revealed that the Sf-9 cells carrying the recombinant viral protein and σΒ could indeed cause an immune response in mice. In addition, the ARV vaccine (commercial poultry Rio S1133 live vaccine) was used as the control group, and the recombinant viruses BacSCjC, BacSC-jB and BacSC-(jC+aB (ie, simultaneous injection of recombinant viruses Baesc-jc and BacSC-σΒ) were used. For the experimental group, and with BacSC and phosphoric acid
Phosphate ^ 驗組及控做之病毒蛋白分卿三組該實驗小鼠進行腹腔 注射。進行實驗小鼠腹驗射之二個星期後,再進行一次 追加注射’並於再次追加注射後六個星期,採集實驗小鼠 之企液進行酵素結合免疫吸附試驗及病毒巾和試驗。結果 如第9圖所示,經ELISA咖如判讀〇D.结果顯示,注 射BacSC及PBS陰性控制組之實驗小鼠金清的elisa值 201006928 均小於0.4。而注射BacSC-aC切B的實驗組之實驗小鼠 血/月的ELISA值兩達2.2。而病毒中和試驗之結果如第1〇 .®:示,】其中以切B组別最高’其抗體力價 可達10 。由此結果可知以重組病毒BacSC_σC與The experimental group of the Phosphate ^ test group and the control virus protein protein were injected intraperitoneally. Two weeks after the experimental mice were tested for abdomen, another additional injection was performed, and six weeks after the additional injection, the experimental mice were collected for enzyme-binding immunosorbent assay and virus towels and tests. Results As shown in Fig. 9, the ELISA coffee was used to interpret 〇D. The results showed that the elisa value of the experimental mice Jinqing, which was injected into the BacSC and PBS negative control groups, was less than 0.4. The experimental mice injected with BacSC-aC cut B had blood/month ELISA values of 2.2. The results of the virus neutralization test are as shown in Section 1.®: ???, where the highest in the cut group B is 'the antibody strength is up to 10%. The results show that the recombinant virus BacSC_σC and
BacSC-σΒ制進行免疫反應之效果顯著,使得—sc· σ C+ σ B (即同時注射重組病毒如观_ ^ c與_ 可搭配佐劑或賦形劑,以應用為家禽里奥病毒次單位標識 料’而桿狀病毒本身可作為該次單倾苗之佐劑。 J 利用pBacSC表現豬瘟病毒蛋白 本發明之_ pBaeSC表現豬如毒蛋白的第一步驟 .係根據豬瘟病毒基因序列設計e〇_f (序列編號11:5,_BacSC-σΒ has a significant effect on the immune response, so that -sc· σ C+ σ B (ie simultaneous injection of recombinant virus such as _ ^ c and _ can be used with adjuvants or excipients for application as a poultry virus virus subunit The marker bacillus itself can be used as an adjuvant for the single sapling. J uses pBacSC to express the porcine prion protein. The first step of the invention is that the pBaeSC expresses a porcine such as a venom protein. E〇_f (sequence number 11:5,_
TTGAACTCGAGGCCGAAAATATAACTCAA-3- ) /EO-R ( 12 : 5f-GCATAGAATTC AGCGCCAAACCAGGT TTT-3 )及 E2-F (序列編號 : 5'-CAGTACTCGAG GCACAAGGCCGGCTAGCC-3') /E2_r (序列編號 14:y_ ◎ CCAAGAATTCAAATTCTGCGAAGTAATC-3,)引子組, 以豬瘟病毒基因做為模板進行聚合酶連鎖反應,以擴增豬 瘟病毒E0基因(大小為675 bp)及E2基因(大小為 . 1074 bp)。將該擴增之豬瘟病毒基因及E2基因以限制 内切酶五⑶及I和户对I進行酵素切割,同時將pBacSC載 體以五coi? I和/V I内切酶進行酵素切割。將pBacSC載 體與豬瘟病毒E0基因及E2基因進行連接作用(ligati〇n) ’以構築重組桿狀病毒載體pBacSC-Εθ及pBacSC-E2。 本發明之利用pBacSC表現豬瘟病毒蛋白的第二步驟 201006928 .係利用Bac-to-Bac®系統將該構築好之pBacSC_E〇及 PfiacSC-E2載體上之特定基因片段藉由轉置作用互換置入 勝任細胞之穿梭載體上,將該經過轉置作用之勝任細胞培 養二至三天,挑選出轉置成功之白色菌落,並進行聚合酶 連鎖反應擴增E0及E2基因片段予以確認,且大量培養 該成功轉置之菌株’再抽取該菌株之重組穿梭載體 ’將細胞轉染試劑(cellfectin reagent)與重組穿梭载體 DNA於至溫_下混合3〇分鐘’取該混合液加入含有sf_9 細胞株之細胞培養盤(well)中,於27 °C培養5小時後 抽出混合液,並於該混合液加入含有10%胎牛血清及三 合一抗生素的TNM-FH培養液,再置於27 °C培養箱培 養3天,進行離心取上清液,該上清液即含有第〇代之 BacSC-EO及BacSC-E2重組桿狀病毒。 本發明之利用pBacSC表現豬瘟病毒蛋白的第三步驟 •係以BacSC-EO及BacSC-E2重組桿狀病毒作為種毒, 重新感染新鮮的Sf-9細胞,三天後收取受感染的sf_9細 胞進行SDS-PAGE電泳及西方墨點法(western bl〇t)分 析。一抗為猪瘟陽性血清’二抗為辣根過氧化物酶(HRp )標記羊抗鼠IgG,結果請參照第ha圖及第iiB圖, 其Lane 1皆為標準條帶(Marker ),Lane 2分別為被 BacSC-EO與BacSC-E2感染之Sf-9昆蟲細胞,Lane 3皆 為被BacSC感染之Sf-9昆蟲細胞,Lane 4皆為未受任何 感染之Sf-9昆蟲細胞,結果顯示以BacSC感染的之Sf-9 昆蟲細胞及Sf-9昆蟲細胞,皆未出現任何蛋白可以被抗 201006928 crC及抗σΒ的一級抗體所辨識;而以Bac:sc-E0及TTGAACTCGAGGCCGAAAATATAACTCAA-3- ) /EO-R ( 12 : 5f-GCATAGAATTC AGCGCCAAACCAGGT TTT-3 ) and E2-F (SEQ ID NO: 5'-CAGTACTCGAG GCACAAGGCCGGCTAGCC-3') /E2_r (SEQ ID NO: 14: y_ ◎ CCAAGAATTCAAATTCTGCGAAGTAATC-3, In the primer group, the polymerase chain reaction was carried out using the classical swine fever virus gene as a template to amplify the E0 gene (675 bp in size) and the E2 gene (1074 bp in size). The amplified swine fever virus gene and the E2 gene were cleaved by restriction endonuclease five (3) and I and H. I, and the pBacSC vector was cleaved with five coi? I and /V I endonucleases. The pBacSC vector was ligated with the CSFV E0 gene and the E2 gene to construct a recombinant baculovirus vector pBacSC-Εθ and pBacSC-E2. The second step of the present invention for expressing a swine fever virus protein using pBacSC is 201006928. The specific gene fragments on the constructed pBacSC_E〇 and PfiacSC-E2 vectors are interchangeably inserted by transposition using the Bac-to-Bac® system. On the shuttle vector of competent cells, the transfected competent cells are cultured for two to three days, and the transfected white colonies are selected, and the E0 and E2 gene fragments are amplified by polymerase chain reaction to confirm and cultured in large quantities. The successfully transfected strain 're-extracting the recombinant shuttle vector of the strain', the cellfectin reagent and the recombinant shuttle vector DNA were mixed for 3 minutes into the temperature_', and the mixture was added to the sf_9-containing cell line. In a cell culture plate, the mixture was cultured at 27 ° C for 5 hours, and the mixture was extracted, and a TNM-FH culture solution containing 10% fetal calf serum and a 3-in-1 antibiotic was added to the mixture, and then placed at 27 °. The culture incubator was incubated for 3 days, and the supernatant was centrifuged, and the supernatant contained the BacSC-EO and BacSC-E2 recombinant baculovirus of the second generation. The third step of the present invention for expressing hog cholera virus protein using pBacSC is to reinfect fresh Sf-9 cells with BacSC-EO and BacSC-E2 recombinant baculovirus as seed venom, and collect infected sf_9 cells three days later. SDS-PAGE electrophoresis and Western blot analysis (western bl〇t) were performed. The primary antibody is porcine sputum positive serum 'secondary antibody is horseradish peroxidase (HRp) labeled goat anti-mouse IgG, the results please refer to the ha chart and the iiB chart, the Lane 1 are standard bands (Marker), Lane 2 Sf-9 insect cells infected with BacSC-EO and BacSC-E2, respectively, Lane 3 are Sf-9 insect cells infected with BacSC, and Lane 4 is Sf-9 insect cells not infected, and the results show None of the Sf-9 insect cells and Sf-9 insect cells infected with BacSC were recognized by the primary antibody against 201006928 crC and anti-σΒ; and Bac:sc-E0 and
BacSC-E2感染的Sf-9昆蟲細胞分別在43及50 KD的大 . 小位置出現被一級抗體辨識之反應;由該西方墨點法分析 之結果可罐認重組桿狀病毒BacSC-EO、BacSC-E2可表現 家禽里奥病毒E0及E2蛋白。為了證明重組蛋白豬瘟病 毋蛋白係表現在昆蟲細胞的細胞膜上,進行本發明之利用 pBacSC表現豬瘟病毒蛋白的第四步驟:係以猪瘟陽性血 ^ '月做為一抗,以免疫螢光(fluorescein isothiocyanate ; FITC)標記的羊抗猪做為二抗;進而標定帶有豬瘟 病毒E0及E2重組蛋白質,以進行共軛聚焦顯微鏡分析 。結果見第12圖,可看出E〇&E2蛋白表現在£蟲細胞 的細胞膜上。 本發明之利用pBacSC表現豬瘟病毒蛋白的第五步驟 :係將純化的重轉狀祕祕過—抗為抗腿的單株 抗體結合後,再與膝體金標記的羊抗鼠IgG第二抗體結合 Ο 最後I過2%的磷鶴酸液滴上複染電鏡觀察,結果如第 圖所示彳以觀察到金粒子結合到重組桿狀病毒的封 套f上,而陰性對照組沒有金粒子結合到病毒的封套膜上 兒月確實在重組桿狀病毒封套膜上表現了重組的E0及 • E2蛋白。 豬瘦^舂E2蛋白應用於次單位疫苗之實驗動物免疫試驗 發明係選用六至八週齡無特定病原之實驗動物進 病毒E2蛋自之免賴驗,其中該實驗動物係小 ,、實驗小鼠之品系為BALB/C。本發明之豬瘟病毒E2 —21 — 201006928 蛋白應用於次單位疫苗的實驗動物免疫試驗第一步驟:係 以BacSC-E2為實驗組,並以CSFV (市售豬痕活毒疫苗) 為對照組,以BacSC及PBS為控制組。取實驗組、對照 組及控制組分別對四組該實驗小鼠進行腹腔注射'。進行實' 驗小鼠腹腔注射之二個星期後,再進行一次追加注射,並 於再次追加注射後六個星期,採集實驗小鼠之血液進行酵 素結合免疫吸附試驗及病毒中和試驗。結果如第14圖所BacSC-E2-infected Sf-9 insect cells showed a reaction recognized by primary antibody at the large and small positions of 43 and 50 KD, respectively. The results of the Western blot analysis confirmed the recombinant baculovirus BacSC-EO, BacSC. -E2 can express poultry virus E0 and E2 proteins. In order to prove that the recombinant protein Swine fever 毋 protein line is expressed on the cell membrane of insect cells, the fourth step of using the pBacSC to express the Swine Fever virus protein of the present invention is carried out: the porcine sputum positive blood is used as the primary antibody to immunize Fluorescent (fluorescein isothiocyanate; FITC)-labeled goat anti-pigs were used as secondary antibodies; the recombinant proteins carrying CSFV E0 and E2 were further calibrated for conjugated focusing microscopy. The results are shown in Fig. 12, and it can be seen that the E〇&E2 protein is expressed on the cell membrane of the insect cell. The fifth step of using the pBacSC to express the classical swine fever virus protein of the present invention is to combine the purified refolded secret-anti-anti-legged monoclonal antibody, and then with the knee gold-labeled goat anti-mouse IgG Antibody binding Ο Last I over 2% of the phosphorheic acid droplets were counterstained by electron microscopy. The results were as shown in the figure to observe the binding of gold particles to the envelope f of the recombinant baculovirus, while the negative control group had no gold particles. On the envelope membrane bound to the virus, the recombinant E0 and E2 proteins were expressed on the recombinant baculovirus envelope membrane. The experimental animal immunization test for pig subcutaneous E2 protein is applied to the sub-unit vaccine. The invention adopts the test animals of six to eight weeks old without specific pathogens to enter the virus E2 egg, which is small, and the experiment is small. The rat strain is BALB/C. The first step of the experimental animal immunization test for the pig prion E2-21-201006928 protein of the invention is applied to the sub-unit vaccine: the BacSC-E2 is used as the experimental group, and the CSFV (commercial pig-toothed live vaccine) is used as the control group. BacSC and PBS were used as control groups. Four groups of the experimental mice were intraperitoneally injected with the experimental group, the control group and the control group. Two weeks after the intraperitoneal injection of the mice, another additional injection was performed, and the blood of the experimental mice was collected for enzyme-binding immunosorbent assay and virus neutralization test six weeks after the additional injection. The result is as shown in Figure 14.
示,經ELISA reader判讀OR5。結果顯示,注射BacSC 及PBS控制組之實驗小鼠血清的ELISA值均小於〇5, 注射CSFV對照組之實驗小鼠血清的EUSA值小於ι 〇 ; 而注射BacSC-E2實驗組之實驗小鼠血清的ELISa值高達 1.5以上。 间It is indicated that OR5 is interpreted by an ELISA reader. The results showed that the ELISA values of the serum of the experimental mice injected with BacSC and PBS control group were less than 〇5, and the EUSA value of the serum of the experimental mice injected with CSFV control group was less than ι 〇; and the serum of experimental mice injected with BacSC-E2 experimental group. The ELISa value is as high as 1.5 or more. between
該病毒中和試驗之結果如下表所示:The results of the virus neutralization test are shown in the following table:
病毒中和抗體力價 由上表可知,BacSC-E2之和試;之病 毒中和抗體力價。由以上之結果可知以重組病毒如观正2 進行免疫反應之效果顯著,使得BacSC_E2可搭配佐劑或 賦形劑,以應用為豬瘟病毒次單位標識疫苗,而桿狀病毒 本身可作為該次單位疫苗之佐劑。 如上所述,本發明泛用型桿狀病毒表面呈現系統, 其係#㈣H ί~ !及_高效率限 —22 — 201006928 制酶切位選殖入重組載體,使得本發明具有可被重複使用 • 於表現多種外源蛋白之功效。 , 雖然本發明已利用上述較佳實施例揭示,然其並非 用以限定本發明,任何熟習此技術者,在不脫離本發明之 精神和範圍之内,當可作各種更動與修改,因此本發明之 保護範圍當視後附之申請專利範圍所界定者為準。 Ο 〇 23 — 201006928 【圖式簡單說明】 第1圖:表現平台pBacSC之構築。 . 第2圖:以聚合酶連鎖反應擴增表現平台pBacSc之 gp64SS-His6及gp64TM-CTD基因片段之電泳圖。 第3圖:重組載體pBacSC-σΒ及pBacSC-ac之構築。 第4A1圖至第4B3圖:BacSC-σΒ及BacSC-aC重組 桿狀病毒感染之Sf-9細胞株之螢光顯微鏡觀察圖。 第5A圖及第5B圖:檢測重組桿狀病毒BacSC_aC、 BacSC-crB表現家禽里奥病毒(jc及crB蛋白之轉潰圖。 第6圖:重組蛋白aC及crB呈現於病毒套膜之螢光顯 微鏡觀察圖。 第7圖:重組蛋白aC及crB呈現於病毒套膜之免疫金 電子顯微鏡觀察圖。 第8圖:重組及σΒ病毒蛋白注射實驗動物之酵素 結合免疫吸附試驗結果圖。 蠢^ 第9圖:感染重組病毒之昆蟲細胞注射實驗動物之酵素 結合免疫吸附試驗結果圖。 第10圖:感染重組病毒之昆蟲細胞注射實驗動物之病 - 毒中和試驗結果圖。 - 第11Α圖及第11Β圖:檢測重組桿狀病毒BacSC_E〇及 BacSC-E2表現諸瘟蛋白之轉潰圖。 第12圖:重組蛋白E0及E2呈現於病毒套膜之榮光顯 微鏡觀察圖。 第13圖:重組蛋白E0及μ呈現於病毒套膜之免疫金 24 — 201006928 電子顯微鏡觀察圖。 第14圖:重組E2病毒蛋白注射實驗動物之酵素結合 免疫吸附試驗結果圖。 【主要元件符號說明】 (無)The virus neutralizing antibody titer can be seen from the above table, the BacSC-E2 sum test; the virus neutralizes the antibody power. From the above results, it is known that the effect of the immune reaction with the recombinant virus such as Guanzheng 2 is remarkable, so that BacSC_E2 can be used together with an adjuvant or an excipient to apply the vaccine as a swine fever virus subunit, and the baculovirus itself can be used as the vaccine. Adjuvant for unit vaccine. As described above, the general-purpose baculovirus surface presentation system of the present invention, which is #(四)H ί~ ! and _ high efficiency limit - 22 - 201006928, is ligated into a recombinant vector, so that the present invention can be reused. • The ability to express a variety of foreign proteins. Although the present invention has been disclosed in the above-described preferred embodiments, it is not intended to limit the invention, and various modifications and changes can be made without departing from the spirit and scope of the invention. The scope of the invention is defined by the scope of the appended claims. Ο 〇 23 — 201006928 [Simple description of the diagram] Figure 1: Construction of the performance platform pBacSC. Fig. 2: Electrophoresis pattern of gp64SS-His6 and gp64TM-CTD gene fragments expressing the platform pBacSc was amplified by polymerase chain reaction. Figure 3: Construction of the recombinant vectors pBacSC-σΒ and pBacSC-ac. Figures 4A1 to 4B3: Fluorescence microscopic observation of BacSC-σΒ and BacSC-aC recombinant baculovirus-infected Sf-9 cell lines. Figure 5A and Figure 5B: Detection of recombinant baculovirus BacSC_aC, BacSC-crB showed poultry virus (jc and crB protein breakdown map. Figure 6: Recombinant proteins aC and crB are present in the viral envelope. Microscopic observation Fig. 7: Recombinant protein aC and crB are presented in the immunogold microscopic observation of the viral envelope. Figure 8: Recombinant and σΒ viral protein injection test animal enzyme combined immunosorbent assay results. Fig. 9: Results of enzyme-binding immunosorbent assays of experimental animals injected with recombinant virus-infected insect cells. Figure 10: Infection of insect cells infected with recombinant virus-infected animal-toxicity test results. - Figure 11 and 11Β图: Detection of recombinant baculovirus BacSC_E〇 and BacSC-E2 showed the breakdown of prion protein. Figure 12: Recombinant proteins E0 and E2 presented in the glory microscopic observation of the viral envelope. Figure 13: Recombinant protein E0 And μ presented in the immunoglobulin of the viral envelope 24-201006928 Electron microscopic observation. Figure 14: Enzyme-binding immunosorbent assay results of recombinant E2 viral protein injection test animals . The main element REFERENCE NUMERALS (None)
——25 — 201006928——25 — 201006928
序列表 . <11〇>國立屏東科技大學 . <120〉泛用型桿狀病毒表面呈現系統及其應用於次單位疫苗之製備 <130〉 95144532 <160〉 7 <170> Patentln version 3.5Sequence Listing. <11〇>National Pingtung University of Science and Technology. <120>General-purpose baculovirus surface rendering system and its application to subunit vaccines<130> 95144532 <160〉 7 <170> ; Patentln version 3.5
<210〉 1 <211〉 69 〇 <212〉 DNA 〈213> 桿狀病毒(baculovirus) <400> 1 ttcatgtttg gtcatgtagt taactttgta attatattaa ttgtgatttt atttttgtac tgtatgatt 69<210> 1 <211> 69 〇 <212> DNA <213> baculovirus <400> 1 ttcatgtttg gtcatgtagt taactttgta attatattaa ttgtgatttt atttttgtac tgtatgatt 69
<210〉 2 <211〉 981 <212> DNA <213〉家禽里奥病毒(Avian retrovirus) <220〉 <221> CDS <222〉(1)...(981) <400〉 1 atg gcg ggt etc aat cca teg cag ega aga gag gtc gtc age ttg ata<210> 2 <211> 981 <212> DNA <213> Avian retrovirus <220><221> CDS <222>(1)...(981) <;400〉 1 atg gcg ggt etc aat cca teg cag ega aga gag gtc gtc age ttg ata
Met Ala Gly Leu Asn Pro Ser Gin Arg Arg Glu Val Val Ser Leu lie 1 5 10 15 ctg tea ttg act teg aac gtg aat ata agt cat ggc gat ttg aeg ccgMet Ala Gly Leu Asn Pro Ser Gin Arg Arg Glu Val Val Ser Leu lie 1 5 10 15 ctg tea ttg act teg aac gtg aat ata agt cat ggc gat ttg aeg ccg
Leu Ser Leu Thr Ser Asn Val Asn lie Ser His Gly Asp Leu Thr Pro 20 25 30 ate tat gaa egg ctg acc aat eta gaa gcg tet aeg gag tta tta cat lie Tyr Glu Arg Leu Thr Asn Leu Glu Ale Ser Thr Glu Leu Leu His 35 40 45 48 96 —26—— 144 192201006928 cgc tcc att tcc gat ata tcc act act gtc tea aat att tet gca aat • Arg Ser lie Ser Asp lie Ser Thr Thr Val Ser Asn lie Ser Ala Asn 50 55 60 « tta caa gac atg acc cat aca ttg gat gat gta act get aat tta gac Leu Gin Asp Met Thr His Thr Leu Asp Asp Val Thr Ala Asn Leu Asp 65 70 75 80 ggt ttg agg acc act gtt act gca ett cag gat tcc gtc tcc att ctg Gly Leu Arg Thr Thr Val Thr Ala Leu Gin Asp Ser Val Ser lie Leu 85 90 95 tet aca aat gtg act gac tta aeg aac aga tcc tet geg cac geg geg ◎ Ser Thr Asn Val Thr Asp Leu Thr Asn Arg Ser Ser Ala His Ala Ala 100 105 110 ata eta tet tea ett cag act aeg gtt gac gga aac tcc act gee ate lie Leu Ser Ser Leu Gin Thr Thr Val Asp Gly Asn Ser Thr Ala lie 115 120 125 tcc aat ttg aag agt gat ate teg teg aac ggt tta get att aca gat Ser Asn Leu Lys Ser Asp lie Ser Ser Asn Gly Leu Ala lie Thr Asp 130 135 140 ctg cag gat cgt gtt aaa tea ttg gag tet acc geg agt cat ggt eta Leu Gin Asp Arg Val Lys Ser Leu Glu Ser Thr Ala Ser His Gly Leu 145 150 155 160 tet ttt teg cct ccg ett agt gtc get gac ggc gtg gtt tea tta gac Ser Phe Ser Pro Pro Leu Ser Val Ala Asp Gly Val Val Ser Leu Asp 165 170 175 atg gac ccc tac ttc tgt tet caa ega gtt tet tta aca tea tac teg Met Asp Pro Tyr Phe Cys Ser Gin Arg Val Ser Leu Thr Ser Tyr Ser 180 185 190 geg gag get caa eta atg caa ttt egg tgg atg gca egg ggt act aac Ala Glu Ala Gin Leu Met Gin Phe Arg Trp Met Ala Arg Gly Thr Asn 195 200 205 gga tea tet gat acc att gac atg acc gtt aac get cac tgt cat gga Gly Ser Ser Asp Thr lie Asp Met Thr Val Asn Ala flis Cys His Gly 240 288 336 384 432 480Leu Ser Leu Thr Ser Asn Val Asn lie Ser His Gly Asp Leu Thr Pro 20 25 30 ate tat gaa egg ctg acc aat eta gaa gcg tet aeg gag tta tta cat lie Tyr Glu Arg Leu Thr Asn Leu Glu Ale Ser Thr Glu Leu Leu His 35 40 45 48 96 —26 — 144 192201006928 cgc tcc att tcc gat ata tcc act act gtc tea aat att tet gca aat • Arg Ser lie Ser Asp lie Ser Thr Thr Val Ser Asn lie Ser Ala Asn 50 55 60 « tta Caa gac atg acc cat aca ttg gat gat gta act get aat tta gac Leu Gin Asp Met Thr His Thr Leu Asp Asp Val Thr Ala Asn Leu Asp 65 70 75 80 ggt ttg agg acc act gtt act gca ett cag gat tcc gtc tcc att Ctg Gly Leu Arg Thr Thr Val Thr Ala Leu Gin Asp Ser Val Ser lie Leu 85 90 95 tet aca aat gtg act gac tta aeg aac aga tcc tet geg cac geg geg ◎ Ser Thr Asn Val Thr Asp Leu Thr Asn Arg Ser Ser Ala His Ala Ala 100 105 110 ata eta tet tea ett cag act aeg gtt gac gga aac tcc act gee ate lie Leu Ser Ser Leu Gin Thr Thr Val Asp Gly Asn Ser Thr Ala lie 115 120 125 tcc aat ttg aag agt gat ate teg teg Aac ggt tta ge t att aca gat Ser Asn Leu Lys Ser Asp lie Ser Ser Asn Gly Leu Ala lie Thr Asp 130 135 140 ctg cag gat cgt gtt aaa tea ttg gag tet acc geg agt cat ggt eta Leu Gin Asp Arg Val Lys Ser Leu Glu Ser Thr Ala Ser His Gly Leu 145 150 155 160 tet ttt teg cct ccg ett agt gtc get gac ggc gtg gtt tea tta gac Ser Phe Ser Pro Pro Leu Ser Val Ala Asp Gly Val Val Ser Leu Asp 165 170 175 atg gac ccc tac ttc tgt Tet caa ega gtt tet tta aca tea tac teg Met Asp Pro Tyr Phe Cys Ser Gin Arg Val Ser Leu Thr Ser Tyr Ser 180 185 190 geg gag get caa eta atg caa ttt egg tgg atg gca egg ggt act aac Ala Glu Ala Gin Leu Met Gin Phe Arg Trp Met Ala Arg Gly Thr Asn 195 200 205 gga tea tet gat acc att gac atg acc gtt aac get cac tgt cat gga Gly Ser Ser Asp Thr lie Asp Met Thr Val Asn Ala flis Cys His Gly 240 288 336 384 432 480
528 576 624 —27 — 672 720201006928 210 215 220 • aga cgc act gat tat atg atg teg tee aeg gga aat etc aeg gtc act Arg Arg Thr Asp Tyr Met Met Ser Ser Thr Gly Asn Leu Thr Val Thr • 225 230 235 240 agt aac gtc gtg tta tta acc ttc gat tta agt gac ata aeg cat ate Ser Asn Val Val Leu Leu Thr Phe Asp Leu Ser Asp lie Thr His lie 245 250 255 cca tea gac eta gca cgt ett gtt ccc agt geg gga ttc caa get geg Pro Ser Asp Leu Ala Arg Leu Val Pro Ser Ala Gly Phe Gin Ala Ala 260 265 270 〇 teg ttc cct gtg gac gta tea ttc acc cgc gat tet geg act cat geg Ser Phe Pro Val Asp Val Ser Phe Thr Arg Asp Ser Ala Thr His Ala 275 280 285 tac caa geg tat ggg gtg tac teg age tea cgt gtc ttc aca att act Tyr Gin Ala Tyr Gly Val Tyr Ser Ser Ser Arg Val Phe Thr lie Thr 290 295 300 ttc cca acc gga ggt gat ggt aca geg aac att cgt tee ttg acc gtg Phe Pro Thr Gly Gly Asp Gly Thr Ala Asn lie Arg Ser Leu Thr Val 305 310 315 320 cgt acc ggc ate gac acc taa ©Arg Thr Gly lie Asp Thr 325 768 816 864 912 960 981 <210〉 3 <211〉 326 <212〉 PRT <213〉家禽里奥病毒(Avian retrovirus) <400〉 3528 576 624 —27 — 672 720201006928 210 215 220 • aga cgc act gat tat atg atg teg tee aeg gga aat etc aeg gtc act Arg Arg Thr Asp Tyr Met Met Ser Ser Thr Gly Asn Leu Thr Val Thr • 225 230 235 240 agt Aac gtc gtg tta tta acc ttc gat tta agt gac ata aeg cat ate Ser Asn Val Val Leu Leu Thr Phe Asp Leu Ser Asp lie Thr His lie 245 250 255 cca tea gac eta gca cgt ett gtt ccc agt geg gga ttc caa get geg Pro Ser Asp Leu Ala Arg Leu Val Pro Ser Ala Gly Phe Gin Ala Ala 260 265 270 〇teg ttc cct gtg gac gta tea ttc acc cgc gat tet geg act cat geg Ser Phe Pro Val Asp Val Ser Phe Thr Arg Asp Ser Ala Thr His Ala 275 280 285 tac caa geg tat ggg gtg tac teg age tea cgt gtc ttc aca att act Tyr Gin Ala Tyr Gly Val Tyr Ser Ser Ser Arg Val Phe Thr lie Thr 290 295 300 ttc cca acc gga ggt gat ggt aca geg aac Att cgt tee ttg acc gtg Phe Pro Thr Gly Gly Asp Gly Thr Ala Asn lie Arg Ser Leu Thr Val 305 310 315 320 cgt acc ggc ate gac acc taa ©Arg Thr Gly lie Asp Thr 325 768 816 864 912 960 981 <210 〉 3 <211> 326 <212> PRT <213>Avian retrovirus <400〉 3
Met Ala Gly Leu Asn Pro Ser Gin Arg Arg Glu Val Val Ser Leu lie 15 10 15Met Ala Gly Leu Asn Pro Ser Gin Arg Arg Glu Val Val Ser Leu lie 15 10 15
Leu Ser Leu Thr Ser Asn Val Asn lie Ser His Gly Asp Leu Thr Pro —28 — 201006928 20 25 30 lie Tyr Glu Arg Leu Thr Asn Leu Glu Ala Ser Thr Glu Leu Leu His 35 40 . 45Leu Ser Leu Thr Ser Asn Val Asn lie Ser His Gly Asp Leu Thr Pro —28 — 201006928 20 25 30 lie Tyr Glu Arg Leu Thr Asn Leu Glu Ala Ser Thr Glu Leu Leu His 35 40 . 45
Arg Ser lie Ser Asp lie Ser Thr Thr Val Ser Asn lie Ser Ala Asn 50 55 60Arg Ser lie Ser Asp lie Ser Thr Thr Val Ser Asn lie Ser Ala Asn 50 55 60
Leu Gin Asp Met Thr His Thr Leu Asp Asp Val Thr Ala Asn Leu Asp 65 70 75 80Leu Gin Asp Met Thr His Thr Leu Asp Asp Val Thr Ala Asn Leu Asp 65 70 75 80
Gly Leu Arg Thr Thr Val TTir Ala Leu Gin Asp Ser Val Ser lie Leu 85 90 95Gly Leu Arg Thr Thr Val TTir Ala Leu Gin Asp Ser Val Ser lie Leu 85 90 95
Ser Thr Asn Val Thr Asp Leu Thr Asn Arg Ser Ser Ala His Ala Ala 100 105 110 lie Leu Ser Ser Leu Gin Thr Thr Val Asp Gly Asn Ser Thr Ala lie 115 120 125Ser Thr Asn Val Thr Asp Leu Thr Asn Arg Ser Ser Ala His Ala Ala 100 105 110 lie Leu Ser Ser Leu Gin Thr Thr Val Asp Gly Asn Ser Thr Ala lie 115 120 125
Ser Asn Leu Lys Ser Asp lie Ser Ser Asn Gly Leu Ala lie Thr Asp O 130 135 140Ser Asn Leu Lys Ser Asp lie Ser Ser Asn Gly Leu Ala lie Thr Asp O 130 135 140
Leu Gin Asp Arg Val Lys Ser Leu Glu Ser Thr Ala Ser His Gly Leu 145 150 155 160Leu Gin Asp Arg Val Lys Ser Leu Glu Ser Thr Ala Ser His Gly Leu 145 150 155 160
Ser Phe Ser Pro Pro Leu Ser Val Ala Asp Gly Val Val Ser Leu Asp 165 170 175Ser Phe Ser Pro Pro Leu Ser Val Ala Asp Gly Val Val Ser Leu Asp 165 170 175
Met Asp Pro Tyr Phe Cys Ser Gin Arg Val Ser Leu Thr Ser Tyr Ser 180 185 190 —29 201006928Met Asp Pro Tyr Phe Cys Ser Gin Arg Val Ser Leu Thr Ser Tyr Ser 180 185 190 —29 201006928
Ala Glu Ala Gin Leu Met Gin Phe Arg Trp Met Ala Arg Gly Thr Asn 195 200 205Ala Glu Ala Gin Leu Met Gin Phe Arg Trp Met Ala Arg Gly Thr Asn 195 200 205
Gly Ser Ser Asp Thr lie Asp Met Thr Val Asn Ala His Cys His Gly 210 215 220Gly Ser Ser Asp Thr lie Asp Met Thr Val Asn Ala His Cys His Gly 210 215 220
Arg Arg Thr Asp Tyr Met Met Ser Ser Thr Gly Asn Leu Thr Val Thr 225 230 235 240Arg Arg Thr Asp Tyr Met Met Ser Ser Thr Gly Asn Leu Thr Val Thr 225 230 235 240
Ser Asn Val Val Leu Leu Thr Phe Asp Leu Ser Asp lie Thr His lie 245 250 255 oSer Asn Val Val Leu Leu Thr Phe Asp Leu Ser Asp lie Thr His lie 245 250 255 o
Pro Ser Asp Leu Ala Arg Leu Val Pro Ser Ala Gly Phe Gin Ala Ala 260 265 270Pro Ser Asp Leu Ala Arg Leu Val Pro Ser Ala Gly Phe Gin Ala Ala 260 265 270
Ser Phe Pro Val Asp Val Ser Phe Thr Arg Asp Ser Ala Thr His Ala 275 280 285Ser Phe Pro Val Asp Val Ser Phe Thr Arg Asp Ser Ala Thr His Ala 275 280 285
Tyr Gin Ala Tyr Gly Val Tyr Ser Ser Ser Arg Val Phe Thr lie Thr 290 295 300 ◎ Phe Pro Thr Gly Gly Asp Gly Thr Ala Asn lie Arg Ser Leu Thr Val 305 310 315 320Tyr Gin Ala Tyr Gly Val Tyr Ser Ser Ser Arg Val Phe Thr lie Thr 290 295 300 ◎ Phe Pro Thr Gly Gly Asp Gly Thr Ala Asn lie Arg Ser Leu Thr Val 305 310 315 320
Arg Thr Gly lie Asp Thr 325Arg Thr Gly lie Asp Thr 325
<210〉 4 <211〉 1104 <212〉 DNA <213〉家禽里奥病毒(Avian retrovirus) <220><210> 4 <211> 1104 <212> DNA <213> Avian retrovirus <220>
<221〉 CDS —30 — 48 201006928 <222〉 (1)...(1104) • <400> 4 atg gag gta cgt gtg cca aac ttt cac teg ttc gtt gaa gga ata aca * Met Glu Val Arg Val Pro Asn Phe His Ser Phe Val Glu Gly lie Thr 15 10 15 tet age tat ttg aag act cct get tgc tgg aat gca cag aca gee tgg<221> CDS — 30 — 48 201006928 <222〉 (1)...(1104) • <400> 4 atg gag gta cgt gtg cca aac ttt cac teg ttc gtt gaa gga ata aca * Met Glu Val Arg Val Pro Asn Phe His Ser Phe Val Glu Gly lie Thr 15 10 15 tet age tat ttg aag act cct get tgc tgg aat gca cag aca gee tgg
Ser Ser Tyr Leu Lys Thr Pro Ala Cys Trp Asn Ala Gin Thr Ala Trp 20 25 30 gac act gtg act ttt cac gtc cct gat gta att aga gtt ggc aat gegSer Ser Tyr Leu Lys Thr Pro Ala Cys Trp Asn Ala Gin Thr Ala Trp 20 25 30 gac act gtg act ttt cac gtc cct gat gta att aga gtt ggc aat geg
Asp Thr Val Thr Phe His Val Pro Asp Val lie Arg Val Gly Asn Ala 35 40 45 o tat tgt tgc tet caa tgt tgt ggt gta ett tat tac ggg act ctg cccAsp Thr Val Thr Phe His Val Pro Asp Val lie Arg Val Gly Asn Ala 35 40 45 o tat tgt tgc tet caa tgt tgt ggt gta ett tat tac ggg act ctg ccc
Tyr Cys Cys Ser Gin Cys Cys Gly Val Leu Tyr Tyr Gly Thr Leu Pro 50 55 60 geg gat gga aat tac ttc cct cat cac aaa tgc cat cag caa cag tacTyr Cys Cys Ser Gin Cys Cys Gly Val Leu Tyr Tyr Gly Thr Leu Pro 50 55 60 geg gat gga aat tac ttc cct cat cac aaa tgc cat cag caa cag tac
Ala Asp Gly Asn Tyr Phe Pro His His Lys Cys His Gin Gin Gin Tyr 65 70 75 80 agg acc gat acc cca ctg etc egg tat gtg ega att ggc aga aeg actAla Asp Gly Asn Tyr Phe Pro His His Lys Cys His Gin Gin Gin Tyr 65 70 75 80 agg acc gat acc cca ctg etc egg tat gtg ega att ggc aga aeg act
Arg Thr Asp Thr Pro Leu Leu Arg Tyr Val Arg lie Gly Arg Thr Thr 85 90 95 ^ gag cat ctg ttg gac caa tat get gtt geg ctg gag tet att get gat C# Glu His Leu Leu Asp Gin Tyr Ala Val Ala Leu Glu Ser lie Ala Asp 100 105 110 cac tat gat gaa ate agt caa ege atg gtc gat gag cca gag aac gatArg Thr Asp Thr Pro Leu Leu Arg Tyr Val Arg lie Gly Arg Thr Thr 85 90 95 ^ gag cat ctg ttg gac caa tat get gtt geg ctg gag tet att get gat C# Glu His Leu Leu Asp Gin Tyr Ala Val Ala Leu Glu Ser Lie Ala Asp 100 105 110 cac tat gat gaa ate agt caa ege atg gtc gat gag cca gag aac gat
His Tyr Asp Glu lie Ser Gin Arg Met Val Asp Glu Pro Glu Asn Asp ' 115 120 125 gaa gtc geg ccc ett gac att gta aeg cgt act gaa tet ate ega agtHis Tyr Asp Glu lie Ser Gin Arg Met Val Asp Glu Pro Glu Asn Asp ' 115 120 125 gaa gtc geg ccc ett gac att gta aeg cgt act gaa tet ate ega agt
Glu Val Ala Pro Leu Asp lie Val Thr Arg Thr Glu Ser lie Arg Ser 130 135 140 gat aag aeg gtt gac ccg gac ttt tgg act tac egg ett gag ega cgtGlu Val Ala Pro Leu Asp lie Val Thr Arg Thr Glu Ser lie Arg Ser 130 135 140 gat aag aeg gtt gac ccg gac ttt tgg act tac egg ett gag ega cgt
Asp Lys Thr Val Asp Pro Asp Phe Trp Thr Tyr Arg Leu Glu Arg Arg 145 150 155 160 96 144 192 240 288 336 384 432 —31 — 480 528201006928 tct gat gat tct cgt cga gac ate gee gca tea tgc tgg aga atg att Ser Asp Asp Ser Arg Arg Asp lie Ala Ala Ser Cys Trp Arg Met lie * 165 170 175 ' gat gca tea tea cgt agt etc act ett cca aat tgt ett gtg tee ccg Asp Ala Ser Ser Arg Ser Leu Thr Leu Pro Asn Cys Leu Val Ser Pro 180 185 190 tct ttg cat tct cgt tee gtc ttt ggt caa atg caa aeg acc acc acc Ser Leu His Ser Arg Ser Val Phe Gly Gin Met Gin Thr Thr Thr Thr 195 200 205 ata tac gat gtt geg geg teg gga aag gee gtt aaa ttt tct ccg atg lie Tyr Asp Val Ala Ala Ser Gly Lys Ala Val Lys Phe Ser Pro Met 〇 210 215 220 gtg get aca eta teg caa cgt gat get ggc cct gta atg ett geg aat Val Ala Thr Leu Ser Gin Arg Asp Ala Gly Pro Val Met Leu Ala Asn 225 230 235 240 get gac cca geg gaa ggt gta tat tea ttt tgg aeg teg cac ttc gee Ala Asp Pro Ala Glu Gly Val Tyr Ser Phe Trp Thr Ser liis Phe Ala 245 250 255 ttc tea ccg etc att ggt gga gtt ggg att aeg gga cag tac get cgt Phe Ser Pro Leu lie Gly Gly Val Gly lie Thr Gly Gin Tyr Ala Arg 260 265 270 gag tea tac cat cac gtg ggt cat cca gtg ett ggg agt ggt aag aag Glu Ser Tyr His His Val Gly His Pro Val lie Gly Ser Gly Lys Lys 275 280 285 __ geg tea cac tac aga aat ctg ttt atg gaa tea tgg cgt ggg tgg tea Ala Ser His Tyr Arg Asn Leu Phe Met Glu Ser Trp Arg Gly Trp Ser _ 290 295 300 aag tea get ttc gca tgc get aca gga atg gag cca get gaa tgt gaa Lys Ser Ala Phe Ala Cys Ala Thr Gly Met Glu Pro Ala Glu Cys Glu 305 310 315 320 tct cgt ctg agg gga cat get ege act atg ett gga ege tct ctg ccg Ser Arg Leu Arg Gly His Ala Arg Thr Met Leu Gly Arg Ser Leu Pro 325 330 335 576 624 672 720 768 816 864 912 960 一 32—— 1008 1056 201006928 aac gtc tgt gac gac gag gtt get cag cag tet ggc gee gtg eta aegAsp Lys Thr Val Asp Pro Asp Phe Trp Thr Tyr Arg Leu Glu Arg Arg 145 150 155 160 96 144 192 240 288 336 384 432 — 31 — 480 528201006928 tct gat gat tct cgt cga gac ate gee gca tea tgc tgg aga atg att Ser Asp Asp Ser Arg Arg Asp lie Ala Ala Ser Cys Trp Arg Met lie * 165 170 175 ' gat gca tea tea cgt agt etc act ett cca aat tgt ett gtg tee ccg Asp Ala Ser Ser Arg Ser Leu Thr Leu Pro Asn Cys Leu Val Ser Pro 180 185 190 tct ttg cat tct cgt tee gtc ttt ggt caa atg caa aeg acc acc acc Ser Leu His Ser Arg Ser Val Phe Gly Gin Met Gin Thr Thr Thr Thr 195 200 205 ata tac gat gtt geg geg teg gga aag gee Gtt aaa ttt tct ccg atg lie Tyr Asp Val Ala Ala Ser Gly Lys Ala Val Lys Phe Ser Pro Met 〇210 215 220 gtg get aca eta teg caa cgt gat get ggc cct gta atg ett geg aat Val Ala Thr Leu Ser Gin Arg Asp Ala Gly Pro Val Met Leu Ala Asn 225 230 235 240 get gac cca geg gaa ggt gta tat tea ttt tgg aeg teg cac ttc gee Ala Asp Pro Ala Glu Gly Val Tyr Ser Phe Trp Thr Ser liis Phe Ala 245 250 255 ttc tea c Cg etc att ggt gga gtt ggg att aeg gga cag tac get cgt Phe Ser Pro Leu lie Gly Gly Val Gly lie Thr Gly Gin Tyr Ala Arg 260 265 270 gag tea tac cat cac gtg ggt cat cca gtg ett ggg agt ggt aag aag Glu Ser Tyr His His Val Gly His Pro Val lie Gly Ser Gly Lys Lys 275 280 285 __ geg tea cac tac aga aat ctg ttt atg gaa tea tgg cgt ggg tgg tea Ala Ser His Tyr Arg Asn Leu Phe Met Glu Ser Trp Arg Gly Trp Ser _ 290 295 300 aag tea get ttc gca tgc get aca gga atg gag cca get gaa tgt gaa Lys Ser Ala Phe Ala Cys Ala Thr Gly Met Glu Pro Ala Glu Cys Glu 305 310 315 320 tct cgt ctg agg gga cat get ege act Atg ett gga ege tct ctg ccg Ser Arg Leu Arg Gly His Ala Arg Thr Met Leu Gly Arg Ser Leu Pro 325 330 335 576 624 672 720 768 816 864 912 960 a 32 - 1008 1056 201006928 aac gtc tgt gac gac gag gtt get Cag cag tet ggc gee gtg eta aeg
Asn Val Cys Asp Asp Glu Val Ala Gin Gin Ser Gly Ala Val Leu Thr 340 345 350 1104 tee ctg cag aag act acc aag ttc act gaa gtg gag tgt ggt tgg taaAsn Val Cys Asp Asp Glu Val Ala Gin Gin Ser Gly Ala Val Leu Thr 340 345 350 1104 tee ctg cag aag act acc aag ttc act gaa gtg gag tgt ggt tgg taa
Ser Leu Gin Lys Thr Oir Lys Phe Thr Glu Val Glu Cys Gly Trp 355 360 365Ser Leu Gin Lys Thr Oir Lys Phe Thr Glu Val Glu Cys Gly Trp 355 360 365
<210〉 5 <211> 367 <212> PRT <213〉家禽里奥病毒(Avian retrovirus) o <400〉 5<210> 5 <211> 367 <212> PRT < 213 > Avian retrovirus o <400>
Met Glu Val Arg Val Pro Asn Phe His Ser Phe Val Glu Gly lie Thr 15 10 15Met Glu Val Arg Val Pro Asn Phe His Ser Phe Val Glu Gly lie Thr 15 10 15
Ser Ser Tyr Leu Lys Thr Pro Ala Cys Trp Asn Ala Gin Thr Ala Trp 20 25 30Ser Ser Tyr Leu Lys Thr Pro Ala Cys Trp Asn Ala Gin Thr Ala Trp 20 25 30
Asp Thr Val Thr Phe His Val Pro Asp Val lie Arg Val Gly Asn Ala 35 40 45 ◎Asp Thr Val Thr Phe His Val Pro Asp Val lie Arg Val Gly Asn Ala 35 40 45 ◎
Tyr Cys Cys Ser Gin Cys Cys Gly Val Leu Tyr Tyr Gly Thr Leu Pro 50 55 60Tyr Cys Cys Ser Gin Cys Cys Gly Val Leu Tyr Tyr Gly Thr Leu Pro 50 55 60
Ala Asp Gly Asn Tyr Phe Pro His His Lys Cys His Gin Gin Gin Tyr 65 70 75 80Ala Asp Gly Asn Tyr Phe Pro His His Lys Cys His Gin Gin Gin Tyr 65 70 75 80
Arg Thr Asp Thr Pro Leu Leu Arg Tyr Val Arg lie Gly Arg Thr Thr 85 90 95Arg Thr Asp Thr Pro Leu Leu Arg Tyr Val Arg lie Gly Arg Thr Thr 85 90 95
Glu His Leu Leu Asp Gin Tyr Ala Val Ala Leu Glu Ser lie Ala Asp 100 105 110 —33 — 201006928Glu His Leu Leu Asp Gin Tyr Ala Val Ala Leu Glu Ser lie Ala Asp 100 105 110 —33 — 201006928
His Tyr Asp Glu He Ser Gin Arg Met Val Asp Glu Pro Glu Asn Asp 115 120 125His Tyr Asp Glu He Ser Gin Arg Met Val Asp Glu Pro Glu Asn Asp 115 120 125
Glu Val Ala Pro Leu Asp lie Val Thr Arg Thr Glu Ser lie Arg Ser 130 135 140Glu Val Ala Pro Leu Asp lie Val Thr Arg Thr Glu Ser lie Arg Ser 130 135 140
Asp Lys Thr Val Asp Pro Asp Phe Trp Thr Tyr Arg Leu Glu Arg Arg 145 150 155 160 o Ser Asp Asp Ser Arg Arg Asp lie Ala Ala Ser Cys Trp Arg Met lie 165 170 175Asp Lys Thr Val Asp Pro Asp Phe Trp Thr Tyr Arg Leu Glu Arg Arg 145 150 155 160 o Ser Asp Asp Ser Arg Arg Asp lie Ala Ala Ser Cys Trp Arg Met lie 165 170 175
Asp Ala Ser Ser Arg Ser Leu Thr Leu Pro Asn Cys Leu Val Ser Pro 180 185 190Asp Ala Ser Ser Arg Ser Leu Thr Leu Pro Asn Cys Leu Val Ser Pro 180 185 190
Ser Leu His Ser Arg Ser Val Phe Gly Gin Met Gin Thr Thr Thr Thr 195 200 205 lie Tyr Asp Val Ala Ala Ser Gly Lys Ala Val Lys Phe Ser Pro Met 210 215 220 ◎Ser Leu His Ser Arg Ser Val Phe Gly Gin Met Gin Thr Thr Thr Thr 195 200 205 lie Tyr Asp Val Ala Ala Ser Gly Lys Ala Val Lys Phe Ser Pro Met 210 215 220 ◎
Val Ala Thr Leu Ser Gin Arg Asp Ala Gly Pro Val Met Leu Ala Asn 225 230 235 240Val Ala Thr Leu Ser Gin Arg Asp Ala Gly Pro Val Met Leu Ala Asn 225 230 235 240
Ala Asp Pro Ala Glu Gly Val Tyr Ser Phe Trp Thr Ser His Phe Ala 245 250 255Ala Asp Pro Ala Glu Gly Val Tyr Ser Phe Trp Thr Ser His Phe Ala 245 250 255
Phe Ser Pro Leu lie Gly Gly Val Gly lie Thr Gly Gin Tyr Ala Arg 260 265 270Phe Ser Pro Leu lie Gly Gly Val Gly lie Thr Gly Gin Tyr Ala Arg 260 265 270
Glu Ser Tyr His His Val Gly His Pro Val lie Gly Ser Gly Lys Lys —34 — 201006928 275 280 285Glu Ser Tyr His His Val Gly His Pro Val lie Gly Ser Gly Lys Lys —34 — 201006928 275 280 285
Ala Ser His Tyr Arg Asn Leu Phe Met Glu Ser Trp Arg Gly Trp Ser 290 295 300Ala Ser His Tyr Arg Asn Leu Phe Met Glu Ser Trp Arg Gly Trp Ser 290 295 300
Lys Ser Ala Phe Ala Cys Ala Thr Gly Met Glu Pro Ala Glu Cys Glu 305 310 315 320Lys Ser Ala Phe Ala Cys Ala Thr Gly Met Glu Pro Ala Glu Cys Glu 305 310 315 320
Ser Arg Leu Arg Gly His Ala Arg Thr Met Leu Gly Arg Ser Leu Pro 325 330 335 〇 Asn Val Cys Asp Asp Glu Val Ala Gin Gin Ser Gly Ala Val Leu Thr 340 345 350Ser Arg Leu Arg Gly His Ala Arg Thr Met Leu Gly Arg Ser Leu Pro 325 330 335 〇 Asn Val Cys Asp Asp Glu Val Ala Gin Gin Ser Gly Ala Val Leu Thr 340 345 350
Ser Leu Gin Lys Thr Thr Lys Phe Thr Glu Val Glu Cys Gly Trp 355 360 365 <210> 6 <211> 1035 <212> DNA <213〉諸疲病毒(Pestivirus) ❹ <220> <221> CDS <222〉 (1)...(1035) * <400> 6 gca caa ggc egg eta gcc tgc aag gaa gat tac agg tac gca ata teg Ala Gin Gly Arg Leu Ala Cys Lys Glu Asp Tyr Arg Tyr Ala lie Ser 15 10 15 tea acc gat gag ata ggg eta ett ggg gcc gga ggt etc acc acc acc Ser Thr Asp Glu lie Gly Leu Leu Gly Ala Gly Gly Leu Thr Thr Thr 20 25 30 48 96 tgg aag gaa "tac aac cac gat ttg caa ctg aat gac ggg acc gtt aag 144 —35 一 192201006928Ser Leu Gin Lys Thr Thr Lys Phe Thr Glu Val Glu Cys Gly Trp 355 360 365 <210> 6 <211> 1035 <212> DNA <213>Pestivirus ❹ <220><221> CDS <222> (1)...(1035) * <400> 6 gca caa ggc egg eta gcc tgc aag gaa gat tac agg tac gca ata teg Ala Gin Gly Arg Leu Ala Cys Lys Glu Asp Tyr Arg Tyr Ala lie Ser 15 10 15 tea acc gat gag ata ggg eta ett ggg gcc gga ggt etc acc acc acc Ser Thr Asp Glu lie Gly Leu Leu Gly Ala Gly Gly Leu Thr Thr Thr 20 25 30 48 96 tgg aag gaa "tac Aac cac gat ttg caa ctg aat gac ggg acc gtt aag 144 —35 a 192201006928
Trp Lys Glu Tyr Asn His Asp Leu Gin Leu Asn Asp Gly Thr Val Lys 35 40 45 gcc agt tgc gtg gca ggt tcc ttt aaa gtc aca gca ctt aat gtg gtc ' Ala Ser Cys Val Ala Gly Ser Phe Lys Val Thr Ala Leu Asn Val Val 50 55 60 agt agg agg tat ttg gca tea ttg cat aag aag get tta ccc act tcc Ser Arg Arg Tyr Leu Ala Ser Leu His Lys Lys Ala Leu Pro Thr Ser 65 70 75 80 gtg aca ttc gag etc ctg ttc gac ggg acc aac cca tea act gag gaa Val Thr Phe Glu Leu Leu Phe Asp Gly Thr Asn Pro Ser Thr Glu Glu 85 90 95 o atg gga gat gac ttc agg tcc ggg ctg tgc ccg ttt gat aeg agt cct Met Gly Asp Asp Phe Arg Ser Gly Leu Cys Pro Phe Asp Thr Ser Pro 100 105 110 gtt gtt aag gga aag tac aat aeg acc ttg ttg aac ggt agt get ttc Val Val Lys Gly Lys Tyr Asn Thr Thr Leu Leu Asn Gly Ser Ala Phe 115 120 125 tat ctt gtc tgc cca ata ggg tgg aeg ggt gtc ata gag tgc aca gca Tyr Leu Val Cys Pro lie Gly Trp Thr Gly Val He Glu Cys Thr Ala 130 135 140 gtg age cca aca act ctg aga aca gaa gtg gta aag acc ttc agg aga Val Ser Pro Thr Thr Leu Arg Thr Glu Val Val Lys Thr Phe Arg Arg 145 150 155 160 gac aag ccc ttt ccg cac aga atg gat tgt gtg acc acc aca gtg gaa Asp Lys Pro Phe Pro His Arg Met Asp Cys Val Thr Thr Thr Val Glu * 165 170 175 aat gaa gat tta ttc tat tgt aag ttg ggg ggc aac tgg aca tgt gtg Asn Glu Asp Leu Phe Tyr Cys Lys Leu Gly Gly Asn Trp Thr Cys Val 180 185 190 aaa ggc gag cca gtg gtc tac aca ggg 踩g eta gta aaa caa tgt aga Lys Gly Glu Pro Val Val Tyr Thr Gly Gly Leu Val Lys Gin Cys Arg 195 200 205 240 288 336 384 432 480 528 576 —36 — 624 672201006928 "tgg "tgt ggc ttc gac ttc gat ggg cct gac gga etc ccg cat tac ccc Trp Cys Gly Phe Asp Phe Asp Gly Pro Asp Gly Leu Pro His Tyr Pro ’ 210 215 220 ata ggt aag tgc att ttg gca aat gag aca ggt tac aga ata gta gat lie Gly Lys Cys lie Leu Ala Asn Glu Thr Gly Tyr Arg lie Val Asp 225 230 235 240 tea aeg gac tgt aac aga gat ggc gtt gta ate age aca gag ggg agt Ser Thr Asp Cys Asn Arg Asp Gly Val Val lie Ser Thr Glu Gly Ser 245 250 255 cat gag tgc ttg ate ggt aac aeg act gtc aag gtg cat gca tea gat His Glu Cys Leu lie Gly Asn Thr Thr Val Lys Val His Ala Ser Asp 〇 260 265 270 gaa aga ttg ggc cct atg cca tgc aga cct aaa gag att gtc tet agt Glu Arg Leu Gly Pro Met Pro Cys Arg Pro Lys Glu lie Val Ser Ser 275 280 285 720 768 816 864 get gga cct gta aag aaa acc tee tgt aca ttc aac tac aca aaa act Ala Gly Pro Val Lys Lys Thr Ser Cys Thr Phe Asn Tyr Thr Lys Thr 290 295 300 912 ttg aag aac agg tac tat gag ccc agg gac age tac ttc cag caa tat Leu Lys Asn Arg Tyr Tyr Glu Pro Arg Asp Ser Tyr Phe Gin Gin Tyr 305 310 315 320 960Trp Lys Glu Tyr Asn His Asp Leu Gin Leu Asn Asp Gly Thr Val Lys 35 40 45 gcc agt tgc gtg gca ggt tcc ttt aaa gtc aca gca ctt aat gtg gtc ' Ala Ser Cys Val Ala Gly Ser Phe Lys Val Thr Ala Leu Asn Val Val 50 50 60 agt agg agg tat ttg gca tea ttg cat aag aag get tta ccc act tcc Ser Arg Arg Tyr Leu Ala Ser Leu His Lys Lys Ala Leu Pro Thr Ser 65 70 75 80 gtg aca ttc gag etc ctg ttc gac ggg Acc aac cca tea act gag gaa Val Thr Phe Glu Leu Leu Phe Asp Gly Thr Asn Pro Ser Thr Glu Glu 85 90 95 o atg gga gat gac ttc agg tcc ggg ctg tgc ccg ttt gat aeg agt cct Met Gly Asp Asp Phe Arg Ser Gly Leu Cys Pro Phe Asp Thr Ser Pro 100 105 110 gtt gtt aag gga aag tac aat aeg acc ttg ttg aac ggt agt get ttc Val Val Lys Gly Lys Tyr Asn Thr Thr Leu Leu Asn Gly Ser Ala Phe 115 120 125 tat ctt gtc Tgc cca ata ggg tgg aeg ggt gtc ata gag tgc aca gca Tyr Leu Val Cys Pro lie Gly Trp Thr Gly Val He Glu Cys Thr Ala 130 135 140 gtg age cca aca act ctg aga aca gaa gtg gta aag acc ttc agg aga Val Ser Pro Thr Thr Leu Ar g Thr Glu Val Val Lys Thr Phe Arg Arg 145 150 155 160 gac aag ccc ttt ccg cac aga atg gat tgt gtg acc acc aca gtg gaa Asp Lys Pro Phe Pro His Arg Met Asp Cys Val Thr Thr Thr Val Glu * 165 170 175 Aat gaa gat tta ttc tat tgt aag ttg ggg ggc aac tgg aca tgt gtg Asn Glu Asp Leu Phe Tyr Cys Lys Leu Gly Gly Asn Trp Thr Cys Val 180 185 190 aaa ggc gag cca gtg gtc tac aca ggg step on g eta gta aaa caa Tgt aga Lys Gly Glu Pro Val Val Tyr Thr Gly Gly Leu Val Lys Gin Cys Arg 195 200 205 240 288 336 384 432 480 528 576 —36 — 624 672201006928 "tgg "tgt ggc ttc gac ttc gat ggg cct gac gga etc Ccg cat tac ccc Trp Cys Gly Phe Asp Phe Asp Gly Pro Asp Gly Leu Pro His Tyr Pro ' 210 215 220 ata ggt aag tgc att ttg gca aat gag aca ggt tac aga ata gta gat lie Gly Lys Cys lie Leu Ala Asn Glu Thr Gly Tyr Arg lie Val Asp 225 230 235 240 tea aeg gac tgt aac aga gat ggc gtt gta ate age aca gag ggg agt Ser Thr Asp Cys Asn Arg Asp Gly Val Val lie Ser Thr Glu Gly Ser 245 250 255 cat gag tgc ttg ate Ggt Aac aeg act gtc aag gtg cat gca tea gat His Glu Cys Leu lie Gly Asn Thr Thr Val Lys Val His Ala Ser Asp 〇260 265 270 gaa aga ttg ggc cct atg cca tgc aga cct aaa gag att gtc tet agt Glu Arg Leu Gly Pro Met Pro Cys Arg Pro Lys Glu lie Val Ser Ser 275 280 285 720 768 816 864 get gga cct gta aag aaa acc tee tgt aca ttc aac tac aca aaa act Ala Gly Pro Val Lys Lys Thr Ser Cys Thr Phe Asn Tyr Thr Lys Thr 290 295 300 912 ttg aag aac agg tac tat gag ccc agg gac age tac ttc cag caa tat Leu Lys Asn Arg Tyr Tyr Glu Pro Arg Asp Ser Tyr Phe Gin Gin Tyr 305 310 315 320 960
atg ett aag ggt gag tat cag tac tgg ttt gac ctg gat geg act gac Met Leu Lys Gly Glu Tyr Gin Tyr Trp Phe Asp Leu Asp Ala Thr Asp 325 330 335 1008 ege cac tea gat tac ttc gca gaa ttt Arg His Ser Asp Tyr Phe Ala Glu Phe 340 345 1035 <210〉 7 <211> 345 <212> PRT <213> 猪盘病毒(Pestivirus) <400> 7 —37 201006928Atg ett aag ggt gag tat cag tac tgg ttt gac ctg gat geg act gac Met Leu Lys Gly Glu Tyr Gin Tyr Trp Phe Asp Leu Asp Ala Thr Asp 325 330 335 1008 ege cac tea gat tac ttc gca gaa ttt Arg His Ser Asp Tyr Phe Ala Glu Phe 340 345 1035 <210> 7 <211> 345 <212> PRT <213> Porcine Virus <400> 7 -37 201006928
Ala Gin Gly Arg Leu Ala Cys Lys Glu Asp Tyr Arg Tyr Ala lie Ser 15 10 15Ala Gin Gly Arg Leu Ala Cys Lys Glu Asp Tyr Arg Tyr Ala lie Ser 15 10 15
Ser Thr Asp Glu lie Gly Leu Leu Gly Ala Gly Gly Leu Thr Thr Thr 20 25 30Ser Thr Asp Glu lie Gly Leu Leu Gly Ala Gly Gly Leu Thr Thr Thr 20 25 30
Trp Lys Glu Tyr Asn His Asp Leu Gin Leu Asn Asp Gly Thr Val Lys 35 40 45Trp Lys Glu Tyr Asn His Asp Leu Gin Leu Asn Asp Gly Thr Val Lys 35 40 45
Ala Ser Cys Val Ala Gly Ser Phe Lys Val Thr Ala Leu Asn Val Val 50 55 60 〇Ala Ser Cys Val Ala Gly Ser Phe Lys Val Thr Ala Leu Asn Val Val 50 55 60 〇
Ser Arg Arg Tyr Leu Ala Ser Leu His Lys Lys Ala Leu Pro Thr Ser 65 70 75 80Ser Arg Arg Tyr Leu Ala Ser Leu His Lys Lys Ala Leu Pro Thr Ser 65 70 75 80
Val Thr Phe Glu Leu Leu Phe Asp Gly Thr Asn Pro Ser Thr Glu Glu 85 90 95Val Thr Phe Glu Leu Leu Phe Asp Gly Thr Asn Pro Ser Thr Glu Glu 85 90 95
Met Gly Asp Asp Phe Arg Ser Gly Leu Cys Pro Phe Asp Thr Ser Pro 100 105 110Met Gly Asp Asp Phe Arg Ser Gly Leu Cys Pro Phe Asp Thr Ser Pro 100 105 110
Val Val Lys Gly Lys Tyr Asn Thr Thr Leu Leu Asn Gly Ser Ala Phe 115 120 125Val Val Lys Gly Lys Tyr Asn Thr Thr Leu Leu Asn Gly Ser Ala Phe 115 120 125
Tyr Leu Val Cys Pro lie Gly Trp Thr Gly Val lie Glu Cys Thr Ala 130 135 140Tyr Leu Val Cys Pro lie Gly Trp Thr Gly Val lie Glu Cys Thr Ala 130 135 140
Val Ser Pro Thr Thr Leu Arg Thr Glu Val Val Lys Thr Phe Arg Arg 145 150 155 160Val Ser Pro Thr Thr Leu Arg Thr Glu Val Val Lys Thr Phe Arg Arg 145 150 155 160
Asp Lys Pro Phe Pro His Arg Met Asp Cys Val Thr Thr Thr Val Glu 165 170 175 —38 — 201006928Asp Lys Pro Phe Pro His Arg Met Asp Cys Val Thr Thr Thr Val Glu 165 170 175 —38 — 201006928
Asn Glu Asp Leu Phe Tyr Cys Lys Leu Gly Gly Asn Trp Thr Cys Val 180 185 190Asn Glu Asp Leu Phe Tyr Cys Lys Leu Gly Gly Asn Trp Thr Cys Val 180 185 190
Lys Gly Glu Pro Val Val Tyr Thr Gly Gly Leu Val Lys Gin Cys Arg 195 200 205Lys Gly Glu Pro Val Val Tyr Thr Gly Gly Leu Val Lys Gin Cys Arg 195 200 205
Trp Cys Gly Phe Asp Phe Asp Gly Pro Asp Gly Leu Pro His Tyr Pro 210 215 220 lie Gly Lys Cys lie Leu Ala Asn Glu Thr Gly Tyr Arg lie Val Asp 〇 225 230 235 240Trp Cys Gly Phe Asp Phe Asp Gly Pro Asp Gly Leu Pro His Tyr Pro 210 215 220 lie Gly Lys Cys lie Leu Ala Asn Glu Thr Gly Tyr Arg lie Val Asp 〇 225 230 235 240
Ser Thr Asp Cys Asn Arg Asp Gly Val Val lie Ser Thr Glu Gly Ser 245 250 255Ser Thr Asp Cys Asn Arg Asp Gly Val Val lie Ser Thr Glu Gly Ser 245 250 255
His Glu Cys Leu lie Gly Asn Thr Thr Val Lys Val His Ala Ser Asp 260 265 270His Glu Cys Leu lie Gly Asn Thr Thr Val Lys Val His Ala Ser Asp 260 265 270
Glu Arg Leu Gly Pro Met Pro Cys Arg Pro Lys Glu lie Val Ser Ser 275 280 285 ❹Glu Arg Leu Gly Pro Met Pro Cys Arg Pro Lys Glu lie Val Ser Ser 275 280 285 ❹
Ala Gly Pro Val Lys Lys Thr Ser Cys Thr Phe Asn Tyr Thr Lys Thr 290 295 300Ala Gly Pro Val Lys Lys Thr Ser Cys Thr Phe Asn Tyr Thr Lys Thr 290 295 300
Leu Lys Asn Arg Tyr Tyr Glu Pro Arg Asp Ser Tyr Phe Gin Gin Tyr 305 310 315 320Leu Lys Asn Arg Tyr Tyr Glu Pro Arg Asp Ser Tyr Phe Gin Gin Tyr 305 310 315 320
Met Leu Lys Gly Glu Tyr Gin Tyr Trp Phe Asp Leu Asp Ala Thr Asp 325 330 335Met Leu Lys Gly Glu Tyr Gin Tyr Trp Phe Asp Leu Asp Ala Thr Asp 325 330 335
Arg His Ser Asp Tyr Phe Ala Glu Phe 340 345 —39Arg His Ser Asp Tyr Phe Ala Glu Phe 340 345 —39
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW097130055A TWI368656B (en) | 2008-08-07 | 2008-08-07 | A universal baculovirus surface display system and application inproduction of subunit vaccine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW097130055A TWI368656B (en) | 2008-08-07 | 2008-08-07 | A universal baculovirus surface display system and application inproduction of subunit vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201006928A true TW201006928A (en) | 2010-02-16 |
| TWI368656B TWI368656B (en) | 2012-07-21 |
Family
ID=44826842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW097130055A TWI368656B (en) | 2008-08-07 | 2008-08-07 | A universal baculovirus surface display system and application inproduction of subunit vaccine |
Country Status (1)
| Country | Link |
|---|---|
| TW (1) | TWI368656B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI670373B (en) * | 2011-02-08 | 2019-09-01 | 淡馬錫生命科學實驗室有限公司 | A novel expression cassette for efficient surface display of antigenic proteins |
| CN110628729A (en) * | 2018-06-25 | 2019-12-31 | 中央研究院 | Baculovirus and composition for detection and prevention of porcine epidemic diarrhea virus infection |
-
2008
- 2008-08-07 TW TW097130055A patent/TWI368656B/en not_active IP Right Cessation
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI670373B (en) * | 2011-02-08 | 2019-09-01 | 淡馬錫生命科學實驗室有限公司 | A novel expression cassette for efficient surface display of antigenic proteins |
| CN110628729A (en) * | 2018-06-25 | 2019-12-31 | 中央研究院 | Baculovirus and composition for detection and prevention of porcine epidemic diarrhea virus infection |
| CN110628729B (en) * | 2018-06-25 | 2024-05-28 | 周美吟 | Baculovirus and composition for detecting and preventing porcine epidemic diarrhea virus infection |
Also Published As
| Publication number | Publication date |
|---|---|
| TWI368656B (en) | 2012-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112876570B (en) | African swine fever virus vaccine and preparation method thereof | |
| US9309536B2 (en) | Recombinant virus-like particles encoded by multi-gene vector | |
| CN112076315A (en) | Nano antigen particle fused with new coronavirus S protein and ferritin subunit, new coronavirus vaccine, and preparation method and application thereof | |
| CN111603557A (en) | A kind of envelope replacement type viral vector vaccine and its construction method | |
| Lindley et al. | Production of monoclonal antibodies using recombinant baculovirus displaying gp64–fusion proteins | |
| EP0349594A1 (en) | Recombinant baculovirus occlusion bodies in vaccines and biological insecticides | |
| CN110093360B (en) | A fusion protein of rabies virus G protein expressing Fc fragment and preparation method thereof | |
| CN110981968B (en) | Fusion protein containing rabies virus G protein, preparation method, application and vaccine thereof | |
| CN110317278A (en) | The fusion protein and its encoding gene of SVV and FMDV, expression vector, cell line, engineering bacteria and vaccine and application | |
| CN109880838A (en) | A kind of recombinant virus and its preparation method and application of the O-shaped foot-and-mouth disease virus multi-epitope gene of secreting, expressing pig | |
| CN104561049A (en) | Recombinant baculovirus expressing porcine parvovirus VP2 protein as well as preparation method and application | |
| CN110951778B (en) | Infectious cDNA clone of canine distemper virus CDV-3 strain and its construction method and application | |
| Tung et al. | Baculovirus surface display of the HA protein of H5N2 avian influenza virus and its immunogenicity against a lethal challenge with H5N1 virus in chickens | |
| CN110951699A (en) | Recombinant rabies virus for expressing structural protein of canine distemper virus and application thereof | |
| KR950001993B1 (en) | Method for preparing hepatitis B surface antigen | |
| CN112029736B (en) | Recombinant pseudorabies virus live vaccine for preventing African swine fever and preparation method thereof | |
| CN111575315A (en) | Rabbit viral hemorrhagic disease virus type II VLP vaccine | |
| TW201006928A (en) | A universal baculovirus surface display system and application inproduction of subunit vaccine | |
| CN109652450A (en) | One boar vaccine carrier | |
| CN112321718B (en) | Self-assembly ferritin-based nano antigen particle, peste des petits ruminants vaccine and preparation method and application thereof | |
| CN115948343A (en) | Stably transfected cell line expressing rabies virus glycoprotein and its construction method and application | |
| CN112439057B (en) | Self-assembly ferritin nano-antigen particle, swine fever vaccine prepared from same and application of swine fever vaccine | |
| CN110066827B (en) | Recombinant baculovirus transfer vector containing porcine pseudorabies virus gB protein gene, recombinant baculovirus and preparation method and application | |
| CN102604898A (en) | VP60 protein recombinant baculovirus carrying type O foot and mouth disease virus B cell epitope | |
| CN104711288A (en) | Recombinant vector, recombinant baculovirus prepared from the same and application of virus in preparation of malaria vaccines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |